Investor-State Dispute Settlement: Human Rights and Regulatory Lessons from Lilly v. Canada

Gervais, D.J.

Published in: UC Irvine law review

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

UvA-DARE is a service provided by the library of the University of Amsterdam (http://dare.uva.nl)
INVESTOR-STATE DISPUTE SETTLEMENT:
HUMAN RIGHTS AND REGULATORY LESSONS FROM LILLY V. CANADA

Daniel J. Gervais

ABSTRACT

The triangular interface between trade, intellectual property (IP) and human rights has yet to be fully formed, both doctrinally and normatively. Adding investor-state dispute settlement (ISDS) to the mix increases the complexity of the equations to solve. Two resultant issues are explored in this Article. First, the Article considers ways in which broader public policy objectives—in particular the protection of human rights—can and should be factored into determinations of whether a state’s action is compatible with its trade obligations and commitments in the state-to-state dispute settlement context. Second, the Article examines whether doctrinal tools used in state-to-state, trade-dispute settlement to make room for public interest considerations port to the investment/ISDS context. The Article uses the recent Lilly v. Canada case as backdrop to illustrate the points made. The Lilly case dealt with an ISDS complaint filed after the revocation of two Canadian patents on pharmaceutical products. The Article approaches the above-mentioned triangular interface from a policy perspective that factors in innovation and investment protection, but also public health, a policy area supported by a human right (to health), and in which states need regulatory autonomy.

1 Ph.D., MAE, Professor of Law, Vanderbilt University Law School. Disclaimer: the Author was an expert retained by Canada in the arbitration. The views expressed are the author’s own, however. The author is grateful to participants at the “IP and Human Rights” symposium at UC Irvine School of Law (Oct. 2016); participants in the Institute of European Studies of Macau “IP as Property” seminar (Nov. 2016); and attendees at my public lecture on the Lilly case at the at Centre for International Intellectual Property Studies in Strasbourg (10 Jan. 2017) for their useful comments on an early draft of this Article. Thanks also to Jose Alvarez, Joel Trachtman and Susy Frankel. All errors are entirely mine.
I. Introduction ........................................................................................................................................ 3

II. Lilly v Canada .................................................................................................................................. 13
   A. The Complaint .................................................................................................................................. 13
   B. Canada’s Counter-Memorial ........................................................................................................... 16
   C. The Role of Chapter 17 .................................................................................................................... 19
   D. Lilly’s Change of Approach ............................................................................................................ 22
   E. Regulatory flexibility ....................................................................................................................... 24

III. Interfaces between Intellectual Property, Human Rights, International Trade & Investment .... 26
   A. Intellectual property and human rights .......................................................................................... 26
   B. Patents and Human Rights ............................................................................................................. 29
   C. The “Right to Health” in Context ................................................................................................... 32

IV. Doctrinal Interfaces .......................................................................................................................... 38
   A. Balancing Human Rights, Trade and Investment ......................................................................... 38
   B. Incorporating human rights in trade and investment disputes ..................................................... 40
   C. Contractarian approaches .......................................................................................................... 42
      1. Filling normative lacunae ............................................................................................................ 43
      2. Incomplete contracts .................................................................................................................... 46
      3. Stipulation for another ................................................................................................................. 48
   D. Express interfaces ......................................................................................................................... 51
      1. Trade ........................................................................................................................................... 51
      2. ISDS ............................................................................................................................................ 54

V. Specific Ways Forward ....................................................................................................................... 57
   A. The Puzzle ...................................................................................................................................... 57
   B. Parameters of an optimal Human Rights/ISDS Interface ............................................................... 58
   C. Directed interpretation ................................................................................................................... 60
   D. Expressly reserving regulatory autonomy ..................................................................................... 63
   E. Imposing obligations on investors ............................................................................................... 63
   F. Factoring in unintended consequences .......................................................................................... 64

Conclusion ............................................................................................................................................ 65

Electronic copy available at: https://ssrn.com/abstract=3061996
I. INTRODUCTION

Investor-State Dispute Settlement (ISDS) is a controversial topic. Its foray in the area of intellectual property (IP) has increased the scope and depth of the controversy. This incursion in the field of IP is the topic of this Article, which explores the resulting controversy using an actual case—perhaps the most prominent one to date—namely the complaint filed by Eli Lilly against Canada under NAFTA Chapter 11. The Article uses this recently decided case to shed light on what could go wrong in the ISDS and intellectual property interface.

The Article considers the issues using two lenses. First, the Article uses a human right lens, echoing Philip Alston’s sentiment that the “relationship between human rights and trade is one of the central issues confronting international lawyers at the beginning of the twenty-first century. . . .” Second, the Article uses a regulatory lens to see how ISDS might impact a state’s ability to regulate not just human rights, but also other key areas of public policy.

Let us first situate ISDS in its international legal context. The nineteenth and twentieth centuries saw international law progress along two axes. First, maintaining state sovereignty as a fundamental tenet, international law began to function in a more “business-like” fashion, getting states to make bargains in which they would limit their sovereign powers in exchange for similar concessions by other states. At the same time, however, international lawyers and scholars gradually devised “a programme for the economic and material betterment of the human race.” This effort was eventually “re-cast into one of global freedom of economic

---


5 See id.

The sovereignty of states remained a cornerstone of the international law edifice erected during this period. This is reflected, inter alia, in the Lotus doctrine, according to which all that is not prohibited by a rule of international law is permitted. Similarly the International Court of Justice stated, in *Military and Paramilitary Activities in and Against Nicaragua (Nicaragua v. United States)*, that “in international law there are no rules, other than such rules as may be accepted by the State concerned, by treaty or otherwise . . .” The theoretical scope of a state’s sovereignty thus depends on what is prohibited by a treaty or other source of international law. A realist might add that, in practice, this also depends on who decides what the law is, whether it was violated, and whether those decisions are enforceable.

The role that state sovereignty should play is still a matter of much discussion in international law, and the Lotus doctrine’s preeminence regularly comes under fire. In his opinion in the *Fisheries* case (United Kingdom v. Norway), for example, Judge Alvarez of the International Court of Justice wrote that the principle reflected in the doctrine “formerly correct, in the days of absolute sovereignty, is no longer so at the present day: the sovereignty of States is henceforth limited not only by the rights of other States but also by other factors . . . which make up what is called the new international law,” including the Charter of the United Nations and resolutions passed by the Assembly of the United Nations.

The Lotus doctrine certainly does not provide a full normative key to understanding the nature of the Westphalian order. For instance, it does not explain whether a state is

---

7 *Id.*


11 The Westphalian order or system emerged after the Peace of Westphalia (1648). It is based on the principle of territorial integrity of sovereign states, which is seen as the primary institutional agent of international law & relations. See Joanna Kulesza & Roy Balleste, *Signs and Portents in Cyberspace: The Rise of Jus Internet as a New Order in International Law*, 23 Fordham Intell. Prop. Media & Ent. L.J. 1311, 1317–1318 (2013).
“naturally” sovereign because it sits at the top of the international legal hierarchy or is a mere organ—and thus also a subject—of international law. If the latter is true, then an international court can “naturally” be called upon to decide if a state is acting within the bounds of the law. If one considers the former option to be correct, then states must willingly accept the jurisdiction of an international court and submit to its findings.\(^\text{12}\)

One way to frame this debate more productively is to consider that states have sovereignty, but that the exercise of sovereignty can come with obligations. A key question is then the enforcement of such obligations by, or on behalf of a supranational institution, such as the United Nations. The question whether states have willingly accepted the jurisdiction or because one considers this supranational institution as having a natural role in doing so is pushed towards the background of the doctrinal picture.\(^\text{13}\) Hans Kelsen and his former student, Sir Hersch Lauterpacht, argued that the United Nations system should include a court with compulsory jurisdiction with a limited mandate to maintain peace.\(^\text{14}\) Kelsen first voiced this idea in 1934.\(^\text{15}\) In the end, however, the Kelsenian dream would not fully materialize, as the International Court of Justice’s jurisdiction is not the “Big Court” he envisaged.\(^\text{16}\) For one thing, its jurisdiction is not compulsory for United Nations members.\(^\text{17}\)

A more powerful form of enforcement would indeed emerge—not in the field of war

\(^\text{12}\) Mario Patrono, *Hans Kelsen: A Peacemaker through Law*, 45 Victoria U. Wellington L. Rev. 647, 649 (2014) (“According to Kelsen, the sovereignty becomes an attribute of the state as the supreme legal order, that is, the sole legal order that doesn’t derive its validity from a superior legal order, but enjoys its own independent validity. . . If we admit the supremacy of international law over domestic law, the ‘sovereignty’ would fade because the state, in Kelsen’s view, would become a mere organ of the international legal community.”).


\(^\text{14}\) Id. at 648, 651. Lauterpacht became a member of the United Nations's International Law Commission from 1952 to 1954 and a Judge of the International Court of Justice from 1955 to 1960.

\(^\text{15}\) HANS KELSEN, THE LEGAL PROCESS AND INTERNATIONAL ORDER 19 (1934) (“[T]he greater the authority of an international court having jurisdiction over all disputes, the less necessary it is to empower it expressly to apply any other than the positive law.”).


\(^\text{17}\) States adhering to the Court may recognize the Court's jurisdiction as “compulsory ipso facto and without special agreement, in relation to any other state accepting the same obligation.” Statute of the International Court of Justice, art. 36, para. 2, Jun. 26, 1945, 59 Stat. 1055, 1060, 33 U.N.T.S. 993.
and peace, but rather in the world of trade law. This is not altogether a huge surprise. Indeed, the impulse to limit state sovereignty to prevent states from behaving badly extended early on into the economic realm. Trade rules are viewed in this context as a means to ensure that states, like Ulysses, limit their sovereignty to withhold “protectionist sirens.” Adding to those normative foundations, the economist Friedrich Hayek suggested that free trade, viewed as a limit to the power of states, was one of the best safeguards of peace. In his mind, this included limits on the controls that a state might compose on trade and the economy more broadly. To that extent, human rights and trade could be said to share some high-level objectives, and trade and foreign investment can be said to work hand-in-hand with development.

International economic liberalization and the enforcement of decisions against states that fail to live up to their liberalization obligations can be traced along three inflection points. The first was the failed attempt to establish an International Trade Organization (ITO) at the Havana conference in 1948, coupled with the successful establishment of the Bretton Woods institutional framework. Although the ITO negotiations failed to establish a new intergovernmental institution, they did yield one important result, namely the signing of the


9 Friedrich A. Hayek, The Road to Serfdom 175 (1944).

10 Id. Professor Ernst-Ulrich Petersmann, in his noted 1991 book, advocated limiting the power of states, inter alia, to guarantee free trade but he offered a different argument, or at least a different version of Hayek’s argument. See Ernst-Ulrich Petersmann, Constitutional Functions and Constitutional Problems of International Economic Law 221–44 (1991).


General Agreement on Tariffs and Trade (GATT).\textsuperscript{23} The GATT included a state-to-state dispute settlement system that differed in at least two important respects from many of its international law cousins: it was mandatory for GATT Contracting Parties and had “teeth,” in the form of trade-based retaliation against a party failing to implement an adverse ruling.\textsuperscript{24} Those teeth were a bit fragile, however, because the losing party in a dispute could oppose adoption of the dispute settlement report by the GATT Contracting Parties and thus compromise its enforceability.\textsuperscript{25} According to Professor Hudec, a number of disputes were not filed in the first place for political and other reasons, thus further limiting the impact of the GATT dispute-settlement system.\textsuperscript{26}

A second inflection point in the strengthening of enforceability was the establishment in 1995 of the World Trade Organization (WTO), which includes an enhanced dispute-settlement system.\textsuperscript{27} The WTO’s teeth, compared to those of the previous GATT system,


\textsuperscript{25} Because the GATT was basically a contract and not a typical intergovernmental organization with “members,” states party to it were simply called contracting parties. Acting together (as a group) to take a collective decision, the capitalized plural \textit{CONTRACTING PARTIES} was used. GATT Article XXV.1 uses “\textit{CONTRACTING PARTIES},” in all capital letters, to mean “the contracting parties acting jointly.” Oct. 30, 1947, 61 Stat. A-3, at A-68, 55 U.N.T.S. 187, at 272. On the “veto” of a party losing a dispute, see Curtis Reitz, \textit{Enforcement of the General Agreement on Tariffs and Trade}, 17 \textit{U. Pa. J. Int’l Econ. L.} 555, 564 (1996) (“General GATT practice was that the \textit{CONTRACTING PARTIES}, or the Council, would take action only if all parties agree; any individual nation could block action. Thus, even the losing party to a dispute could block action by the \textit{CONTRACTING PARTIES} or the Council.”).

\textsuperscript{26} See ROBERT E. HUDEC, \textit{GATT Legal System and World Trade Diplomacy} 185 (1993).

\textsuperscript{27} See Pieter Jan Kuijper, \textit{The New WTO Dispute Settlement System: The Impact on the European Community}, 29:6 \textit{J. World Trade} 49, 57 (1995); Joseph H.H. Weiler, \textit{The Rule of Lawyers and the Ethos of Diplomats: Reflections on the Internal and External Legitimacy of WTO Dispute Settlement}, 13 \textit{Am. Rev. Int’l Arb.} 177, 197 (2002) (“Inevitably, then, with ever increasing sophistication, the WTO legal paradigm shift occasioned by the acceptance of compulsory adjudication with binding outcomes has attracted most comment. And with good empirical justification. Measured in quantitative terms, Panel and the Appellate Body activity under the new DSU can be described as frenetic. Equally inevitably WTO dispute settlement in general and the Appellate Body and its jurisprudence in particular are taking their
grew significantly longer. Clearly, “sovereignty” lost a sizeable share of its normative heft in the
WTO exercise. A number of key actors, including multinational corporations, were pushing for
tough norms to be imposed on and enforced against states where they were doing (or were
planning to do) business. This meant, inter alia, enforcing intellectual property rights and
establishing rules against expropriation. It led to the shift in the entire field of intellectual
property from a set of technical rules administered by its own UN specialized agency (the World
Intellectual Property Organization (WIPO), the origins of which date back to the 1880s) to the
world of trade, and eventually the WTO Agreement on Trade-Related Aspects of Intellectual
Property Rights (TRIPS). A question that emerges in connection with this shift is whether the
WTO dispute settlement system is self-contained, or whether—and if so how—it can consider
norms extrinsic to the WTO regime, including human rights.

The third and last inflection point represents a major step in the path towards a
further reduction in state sovereignty. That step is investor-state dispute settlement (ISDS), a
process that forms part of most recent trade and investment agreements. While all steps in the
story systematically whittled away state sovereignty, ISDS marks a paradigmatic shift. ISDS is
the result of a move towards recognizing the role of multinational corporations as international
legal persons that compete with states for the policy space or have a special say in policy setting
notably because they can offer direct investment in exchange for policy decisions. The two
main contours of the so-called “post-Westphalian” system are: “1) limited international legal

personality for non-state actors; 2) qualified sovereignty for state actors, partly but not exclusively due to a) devolution of sovereignty to local or private entities (localization and privatization) and b) sublimation of sovereignty into transnational international organizations. ISDS is a major step in that context: multinational corporations are given a right to sue states in binding and mandatory arbitration proceedings.

Specifically, ISDS provides multinational corporations a right to sue states that are parties to an investment treaty (such as a bilateral investment treaty or BIT) or a trade agreement containing an investment protection chapter for direct or indirect expropriation, referred to together as international investment treaties (IIAs). Investment protection clauses are now standard in IIAs. According to the United Nations Conference on Trade and Development (UNCTAD), as of 2015 there were 3,304 known IIAs (2,946 BITs and 358 other treaties with investment provision (TIPs)), not all of which are in force, however.

The emergence of ISDS goes well beyond the mere recognition of international legal personality for multinational corporations: it marks a sharp turn in the regulation of the activities of such corporations by individual states where they invest and do business. The scope of the shift compared to state-to-state dispute settlement (i.e., among “equals”) can be measured by comparing ISDS with the 1974 Charter of Economic Rights and Duties of States adopted by the

31 Sweet, supra note 29, at 45 (emphasis added).
32 See José E. Alvarez, Are Corporations “Subjects” of International Law?, 9 SANTA CLARA J. INT’L L. 1, 31 (2011) (suggesting that “international lawyers should spend their time addressing which international rules apply to corporations rather than whether corporations are or are not “subjects” of international law); Glen Kelley, Multilateral Investment Treaties: A Balanced Approach To Multinational Corporations, 39 COLUM. J. TRANSNAT’L L. 483, 489–490 (2001). Interestingly, in Kiobel v. Royal Dutch Petroleum Co. 621 F.3d 111, 131 (2d Cir. 2010), the Court of Appeals for the Second Circuit decided that corporate liability was not a rule of customary international law applicable under the Alien Tort Statute (ATS), 28 U.S.C. § 1350 (2012).
35 See UNCTAD Report, supra note 33, at 101. Not all of those instruments are currently in force.
UN General Assembly. The Charter notes, inter alia, that states have the right “[t]o regulate and supervise the activities of transnational corporations within [their] national jurisdiction and [to] take measures to ensure that such activities . . . conform with [their] economic and social policies.” It imposes a duty on transnational corporations not to “intervene in the internal affairs of a host State.” ISDS is arguably exactly the opposite. Where states A and B have agreed to an ISDS obligation in a treaty, ISDS provides a binding forum where a corporation in state A can challenge a measure taken by the government of state B affecting the corporation’s investments in state B.

ISDS was and probably still is a good idea to attract foreign investment, especially in countries where the legal system may not be effective at imposing remedies against the state. It is so widespread, however, that it no longer marks a comparative advantage (over states that do not provide it); instead states that do not have investment protection (including ISDS) may be at a comparative disadvantage.

The first plurilateral agreement to contain ISDS provisions was NAFTA. ISDS forms part of the second version of the Trans-Pacific Partnership. It likely will form part of the

36 G.A Res. 3281 (XXIX) (Dec. 12, 1974).
37 Id. at art. 2(2).
38 Id.
39 See Timothy J. Feighery, Rule of Law in the Emerging Development Agenda: On Finding the Optimal Role for Investment Treaties, 21 Sw. J. Int’l L. 297, 299 (2015). (“The ISDS may broadly be defined as an international law-based system that is founded mostly on thousands of bilateral investment treaties (BITs) and some multilateral investment-related treaties that protect, on a reciprocal basis, the investors of each state when they make investments in other states. . . . By this system, sovereigns agree to privatize the dispute resolution process for covered investments. In this way, foreign investors are protected against the traditional home field advantage that sovereigns may enjoy via their national court systems.”)
40 See supra note 35 and accompanying text.
41 NAFTA, supra note 2; see Vivian H.W. Wang, Note, Investor Protection or Environmental Protection? “Green” Development under CAFTA, 32 Colum. J. Envtl. L. 251, 260 (2007) (“The inclusion of an ISDS-type mechanism within a BIT was first adopted in NAFTA and was heralded as an advancement in the resolution of international trade disputes as it ‘grant[ed] individual foreign investors standing to sue host governments without requiring the participation or acquiescence of the investor's home government.’”) (notes omitted); see also William L. Owens (NY-21) & R. Andrew Fitzpatrick, Investment Arbitration Under NAFTA Chapter 11: A Threat To Sovereignty Of Member States?, 39 Can.—U.S. L.J. 55 (2015). Investment protection emerged in the bilateral investment treaty between Germany and Pakistan of Nov. 25, 1959. Treaty for the Promotion and Protection of Investments (with
Transatlantic Trade and Investment Partnership (TTIP)—if that agreement is ever finalized—which itself is modeled after a vast number of bilateral investment agreements (BITs). Put differently, ISDS is here, and it seems here to stay. Indeed, “[w]ith 70 cases initiated in 2015, the number of new treaty-based, investor-state arbitrations set a new annual high. Following the recent trend, a high share of cases (forty percent) were brought against developed countries.” ISDS provisions already bind (or soon may) the United States with most of its significant trading partners, including Canada, Mexico, and the EU, and its importance is growing.

ISDS has (finally) started to make the headlines, for example in the United States in 2016 when the Keystone XL pipeline project was rejected by President Obama. That specific example was heralded as evidence of ISDS giving corporations too much power over sovereign public policy.

---


43 See Joseph H.H. Weiler, Editorial, European Hypocrisy: TTIP and ISDS, 25 EUR. J. INT’L L. 963, 964 (2014) (“The ISDS chapter in the TTIP is essentially modelled (for good and for bad) on similar regimes in thousands (!) of BITs in force all over the world. Almost all European Member States, among them the shrillest objectors to the ISDS in the TTIP, are not only signatories to such agreements but are heavy users thereof.”) While BITs by definition contain “investment protection” in the form of ISDS, not all TIPs contain them, though a clear majority do. Of the 358 TIPs just mentioned, 132 contained investment provisions similar to those in BITs, and another thirty-two contained “limited” investment protection (for example, national treatment with respect to commercial presence or free movement of capital relating to direct investments). See id. at 102.

44 Id. at xii.

45 See Christopher R. Drahozal, New Experiences of International Arbitration in the United States, 54 AM. J. COMP. L. 233, 246–47 (2006) (“Although investor-state arbitration dates back at least to the Jay Treaty of 1794, in recent years the number of investment arbitration proceedings has increased dramatically. To illustrate: claimants filed a total of three treaty-based cases with the World Bank’s International Centre for Settlement of Investment Disputes (ICSID) from its inception through 1994. In the next ten years—through November 2004—claimants filed an additional 103 cases. Investment arbitrations also are notable for their high stakes: claimants regularly seek to recover hundreds of millions or even billions of dollars, and the claims may involve sensitive issues of national policy.”) (footnotes omitted).

decisions.47 One can fairly ask, therefore, whether and if so how ISDS meshes with a state’s right to regulate its own public policy within its borders.

Limits on state sovereignty are often well-grounded, for example, when they are supported by a benevolent world community policing human rights.48 But what happens when international law is used to limit the protection of human or fundamental rights that a state (or supranational body, such as the European Union) wants to protect (in the form of a limit on an intellectual property right or restriction on the use of personal data, for example) because it could amount to an alleged expropriation? This is where ISDS takes us now, as it is used to enforce investment protection with little or no doctrinal space to acknowledge—let alone defer to—human rights and other public interest norms and associated policies that a state might wish to apply in its own territory. That, in a nutshell, is the issue at the core of this Article.

The Article proceeds as follows. In Part II, the Article presents the Lilly case, which it uses to explicate how human rights issues might arise in the context of ISDS cases involving intellectual property. In Part III, the Article examines various aspects of the substantive interface between trade, investment, intellectual property, and human rights. This includes the (human) right to health and the regulation of pharmaceutical products from a public health perspective. Part IV reviews various doctrinal mechanisms used (with varying degrees of success) in a trade context to solve this complex equation and considers whether these mechanisms can be used in an ISDS context. Part V offers paths forward.

47 See id. at 130 (“[T]he fact that TransCanada is suing the United States government at all shows that Chapter 11 provides corporations with too much leverage over elected governments through the current model of ISDS.”).

48 The Rt. Hon. The Lord Millet, The Pinochet Case — Some Personal Reflections, in INTERNATIONAL LAW 10 (Malcolm D. Evans ed., 2d ed. 2006) (“No longer is international law a matter which concerns sovereign States alone. It marches with human rights law to protect individuals from State action. The world community has finally decided that the way a sovereign State treats its own nationals is not a purely internal matter.”).
II. **Lilly v. Canada**

This Part provides the reader not familiar with the details of the *Lilly* case with a glimpse into the arguments made by the parties that are relevant for the purposes of this Article. It is not intended to provide a full picture of the case.\(^{49}\)

*Lilly v. Canada* was heard at the International Centre for Settlement of Investment Disputes (ICSID), the forum of choice for NAFTA investor-state disputes, and according to the United Nations Commission on International Trade Law (UNCITRAL\(^{50}\)) Arbitration Rules.\(^{50}\) ICSID is known for the confidentiality and effectiveness of its services.\(^{51}\) Hearings are not public and calls for more transparency have been made, although memorials (briefs) and expert reports, as well as tribunal orders are generally made available to the public on the ICSID website.\(^{52}\)

The award (decision) of the tribunal was made available in March 2017.\(^{53}\)

Let us examine Lilly’s claims and Canada’s response.

### A. The Complaint


\(^{53}\) *Eli Lilly & Co. v. Canada*, ICSID Case No. UNCT/14/2, Final Award, ¶¶ 198, 310, 349 (Mar. 16, 2017), http://icsidfiles.worldbank.org/icsid/ICSIDBLOBS/OnlineAwards/C3544/DC10133_En.pdf. The Award was made available to the parties on March 16, 2017. The Parties had ten days to identify confidential information, if any, in the Award before its release to the public ten days later.
ISDS, HUMAN RIGHTS AND REGULATORY FLEXIBILITY (DRAFT)

Eli Lilly’s complaint against Canada was filed under chapter 11 of NAFTA. That chapter is meant to protect investments made in a NAFTA party by a company based in another NAFTA party. Interestingly, although “intellectual property” is often mentioned in IIAs in the definition of “investment,” this is not the case in NAFTA, at least not directly. The inclusion of intellectual property in the definition of the term “investment” is controversial from a normative perspective when it leads to a challenge to a state’s intellectual property and innovation policy. One could argue that it would be much less so, or even not controversial at all, if the inclusion of intellectual property were limited to actual expropriation (e.g., when state A takes the title to a patent or copyright belonging to company B to keep it or transfer it to a third party).

Actual expropriation is not the fact pattern in Lilly v. Canada. The Lilly case relates to the invalidation of two Canadian patents on its drugs Zyprexa and Strattera (atomoxetine and olanzapine) by Canadian courts for failure to meet one of the core patentability criteria, namely the utility requirement, one of the basic patentability criteria in U.S. and Canadian patent law. The claimant (Lilly) contended that the adoption of a “new, radically different standard for determining whether inventions fulfill that requirement” (the “promise of the patent” doctrine discussed below) amounted to an “uncompensated expropriation, in violation of Article 1110 of NAFTA.”

The claimant alleged that the promise of the patent doctrine violated the intellectual

54 See id. at ¶ 95.
55 See NAFTA, supra note 2, ch. 11.
57 See Ruth L. Okediji, Is Intellectual Property “Investment”? Eli Lilly v. Canada and the International Intellectual Property System, 35 U. PA. J. INT’L L. 1121, 1124 (2014) (“Although the definition of ‘investment’ contained in most investment treaties mention intellectual property, the obligations, expectations, and enforcement aspects of these treaties are largely undeveloped. Moreover, the doctrinal, policy, and structural differences between BITs and the TRIPS Agreement have rarely been meaningfully analyzed, leaving a gap in the international law of intellectual property. That is the gap Eli Lilly now seeks to exploit.”) The Article returns to this issue in greater depth in Parts IV and V infra.
59 Id. at 1–2.
property chapter (Chapter 17) of NAFTA, which “requires Canada to provide patents to
inventions, in all fields of technology, that are ‘new, result from an inventive step, and are
capable of industrial application [i.e., have utility],’” arguing that if “Canada can unilaterally
reinterpret a core legal term in such a stark manner and with such severe consequences, legally
operative words in NAFTA with internationally-accepted meanings could be susceptible to
unilateral re-definition, such that NAFTA will no longer establish foundational requirements for
patent protection.” 60 In other words, Lilly was trying to use investment chapter of NAFTA to
challenge the compatibility of the application of a patentability criterion by Canadian courts (in
which it undeniably received due process) with Canada’s substantive IP obligations in the patent
section of chapter 17 of NAFTA, which are broadly similar to those in the TRIPS agreement. 61
The word “unilateral” used twice in the short quotation above betrays Lilly’s thinking: the
exercise of state sovereignty is seen as a “unilateral” measure.

A second line of Lilly’s argument was that the interpretation of the notion of utility
by Canadian courts violated Canada’s obligations to afford “fair and equitable treatment” (FET)
to Lilly’s investments under Article 1105 of NAFTA. 62 Specifically, Lilly alleged that the
promise of the patent doctrine violated: (i) protection against arbitrary treatment (the doctrine is
completely unpredictable and unreasonably difficult to satisfy); (ii) protection of legitimate,
investment-backed expectations; and (iii) protection against discriminatory treatment. 63

Lilly also argued that it “relied on Canada’s patent law when it sought patent
protection for Zyprexa and Strattera and launched those drugs in Canada,” and that the patents
had been issued “after a careful review by Canada’s patent examiners in light of Canada’s utility
requirement at the time.” 64 These last two arguments, it seems, could be rephrased as arguing
that any invalidation by a court of an issued patent amounts to expropriation, and that any

60 Id. at 5–6 (emphasis added).
61 For a discussion of NAFTA Chapter Seventeen and TRIPS, see Eli Lilly & Co. v. Canada, ICSID Case
No. UNCT/14/2, Expert Report of Daniel J. Gervais, at 18–20 (Jan 26. 2015),
62 Eli Lilly & Co. v. Canada, ICSID Case No. UNCT/14/2, Claimant’s Memorial, at 6 (Sept. 29, 2014),
63 Id. at 6–7.
64 Id. at 7.
significant change in the interpretation of a patentability criterion could also amount to expropriation under NAFTA.

B. Canada’s Counter-Memorial

In its counter-memorial, the Government of Canada noted, first, that the claimant received due process before Canadian courts (a fact not in dispute) and was simply disappointed with the outcome of two patent trials. That did not amount to a breach of the relevant obligations. Rather, according to the respondent, “[t]he threshold for a violation of the minimum standard of treatment is high and requires a finding of egregious or manifestly unfair behaviour” under customary international law.65 Specifically, Canada alleged that the claimant had failed “to prove that the theory of ‘legitimate expectations’ has become a rule of customary international law” protected by NAFTA Article 1105(1) and, moreover, that “regardless of its status generally in international law, it is a doctrine which fundamentally cannot be applied to judgments of the domestic judiciary acting in an adjudicative function of domestic statutory interpretation.”66

On the issue of the alleged change in the interpretation of the utility requirement by Canadian courts, Canada countered on several fronts. It noted that:

[Even if the theory of legitimate expectations is now a rule of custom protected under Article 1105(1), Claimant could not have had a “legitimate expectation” of how a court would rule in the future in light of the law, facts, evidence and other considerations presented before the court at the time of challenge. To assert otherwise would give every disappointed litigant an automatic remedy in international law against any adverse domestic ruling that it “expected” to win.67

66 Id. at 115.
67 Id.; see also Henning Grosse Ruse-Kahn, Litigating Intellectual Property Rights in Investor-State Arbitration: From Plain Packaging to Patent Revocation (Univ. of Cambridge Faculty of Law Legal Studies Research Paper Series, Paper No. 52, 2014), http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2463711 (“In Eli Lilly vs. Canada, the investor hence cannot legitimately expect from the grant of patents by the Canadian Patent Office (CPO) that those remain free from any validity challenges in the courts. Also a change in how the Canadian courts apply
The United States, in a submission noted along similar lines that:

The concept of “legitimate expectations” is not a component element of “fair and equitable treatment” under customary international law that gives rise to an independent host State obligation. An investor may develop its own expectations about the legal regime governing its investment, but those expectations impose no obligations on the State under the minimum standard of treatment. The United States is aware of no general and consistent State practice and *opinio juris* establishing an obligation under the minimum standard of treatment not to frustrate investors’ expectations . . . . Moreover, the concept of “legitimate expectations” is particularly inapt in the context of judicial measures.68

Canada also argued that the “promise of the patent” doctrine was not new in Canadian law, as Canadian academics and a well-known Canadian expert retained by the government of Canada demonstrated.69 A 1981 quote from the Supreme Court of Canada opinion should suffice to illustrate the validity of Canada’s argument:70

There is a helpful discussion in *Halsbury’s Laws of England*, (3rd ed.), vol. 29, at p. 59, on the meaning of ‘not useful’ in patent law. It means ‘that the invention will not work, either in the sense that it will not operate at all, or, more broadly, *that it will not do what the specification promises that it will do*’. . . . The discussion in *Halsbury’s Laws of England* . . . continues:

… the practical usefulness of the invention does not matter, nor does its commercial utility, *unless the specification promises commercial utility*, nor does it matter whether the invention is of any real benefit to the public, or particularly suitable for the purposes suggested. . . .

and concludes:

… it is sufficient utility to support a patent that the invention gives either a new article, or a better article, or a cheaper article, or affords the public a useful choice. . . .

---


Canadian law is to the same effect…71

It seems plain from the above that promises made by a patent applicant in patent specifications were considered relevant and clearly were a known factor in utility analyses in Canadian law, at least as far back as 1981. The tribunal agreed with Canada on that point.72 Canada’s counter-memorial also noted in this context that, even if the promise of the patent doctrine was considered to change the interpretation of the utility criterion, changes in the interpretation of patentability criteria by courts in all three NAFTA parties are common, and sometimes significant.73 This happened recently in several opinions of the United States Supreme Court for example.74 Here again, the tribunal agreed.75

Lilly tried to argue that the notion of utility in Canada should be defined basically the same way that it is in the United States (and therefore practically nonexistent as a substantive threshold). Canada countered that (i) the U.S. definition is not internationally binding on other nations and (ii) that the notion of utility does different normative work (if any) in the United States because the notions of written description and enablement (which do not exist as such in Canadian law) perform essentially the same function as the Canadian notion of utility.76

---


72 See Lilly Award, supra note 3, ¶¶ 318–23.


75 See Eli Lilly Co. v. Canada, ICSID Case No. UNCT/14/2, Final Award, at ¶¶ 310, 386 (Mar. 16, 2017) (noting that “evolution of the law through court decisions is natural, and departures from precedent are to be expected” and referring to “incremental and evolutionary changes” in the interpretation of the utility criterion).

Relatedly, Lilly argued, as Valentina Vadi explains, that it faced “more arduous patent standards in Canada than a Canadian investor might face in other jurisdictions, such as the United States and Europe.” As Vadi notes, “[T]his form of extraterritorial analogy is highly unusual in national treatment claims before arbitral tribunals, given the regulatory diversity of IP laws across the globe, and is likely not going to be accepted by the Arbitral Tribunal.” Indeed, the Tribunal noted that it was “difficult to see how a comparison across jurisdictions can demonstrate a change over time within a single jurisdiction.”

C. The Role of Chapter 17

Canada disagreed both that there was a violation of the substantive intellectual property chapter (Chapter 17) of NAFTA and the ISDS tribunal should consider that alleged violation to begin with. The patent-related provisions contained in that chapter, which was negotiated at about the same time as the TRIPS agreement, are largely similar to those found in TRIPS. Lilly’s argument was not about investment protection proper, but about the compatibility of Canadian law with obligations undertaken vis-a-vis other states (Mexico and the United States).

It is necessary to explain how Lilly managed to concoct this argument, as this understanding will become relevant below. Normally, a disagreement on the application of intellectual property norms contained in the TRIPS Agreement or NAFTA would be subject to

(“Claimant also fails to acknowledge that U.S. law reaches many of the same results as do Canada’s utility rules, through its analogous ‘enablement’ and ‘written description’ requirements.”); Eli Lilly & Co. v. Canada, ICSID Case No. UNCT/14/2, Second Report of Dr. Daniel Gervais, at 3 (Dec. 7, 2015), https://www.italaw.com/sites/default/files/case-documents/ITA%20LAW%207018.pdf (“Claimant’s argument now seems to be that only certain definitions of utility are acceptable (basically, the current U.S. definition) under NAFTA.”).


78 Id. at 181–82.

79 Eli Lilly & Co. v. Canada, ICSID Case No. UNCT/14/2, Final Award, at ¶ 377 (Mar. 16, 2017).


81 See infra Part IV.
state-to-state dispute settlement under the relevant agreement. ISDS in this context is viewed as a way to achieve indirectly what a corporation cannot do directly (because it cannot convince its host state to file a WTO case). Lilly’s argument hangs on a provision in NAFTA that seems to exclude precisely this type of situation from the purview of investor-state disputes. That provision is Article 1110(7), which reads as follows:

This Article does not apply to the issuance of compulsory licenses granted in relation to intellectual property rights, or to the revocation, limitation or creation of intellectual property rights, to the extent that such issuance, revocation, limitation or creation is consistent with Chapter Seventeen (Intellectual Property).

Lilly’s argument in this respect was that it had “demonstrated that Canada’s measures were cognizable expropriations because they violated Canada’s obligations in Chapter 17 of NAFTA (a basis for liability that Article 1110(7) contemplates).” Basically, the argument rests on the fact that, if the investor can demonstrate that the revocation (or other measure) mentioned in article 1110(7) was not “consistent with Chapter Seventeen,” then it was fair game under Chapter 11 (ISDS).


83 See Gaetan Verhoosel, The Use of Investor-State Arbitration Under Bilateral Investment Treaties to Seek Relief for Breaches of WTO Law, 6 J. INT’L ECON. L. 493, 503–06 (2003). It is true that there have been few TRIPS disputes and that many did not provide relief for the corporations that had requested that the cases be brought. See Joost Pauwelyn, The Dog that Barked but Did Not Bite: 15 Years of Intellectual Property Disputes at the WTO, 1 J. INT’L DISP. MGMT. 389, 393, 395 (2010).

84 NAFTA art. 1110(7) (emphasis added).

Canada disagreed. It noted in its rejoinder that:

The inference that Claimant is asking the Tribunal to draw is a logical fallacy, known as the fallacy of denying the antecedent. In essence, the problem with the reasoning is that it ignores the other reasons why something may or may not have occurred. The most classic example involves the following syllogism: “If it is raining, then the streets are wet.” . . . Applied to this case, the relevant conditional statement would be: “If a measure is consistent with Chapter 17, then it is consistent with Article 1110.” From this, one cannot infer, as Claimant suggests, that because a measure is inconsistent with Chapter 17, it is inconsistent with Article 1110. There could be many other reasons why the measure is consistent with Article 1110. Claimant’s interpretation perverts the logic of Article 1110(7) by transforming what was intended to be a shield for the NAFTA Parties in a sensitive area into a sword for disappointed patent litigants to wield. 86

Mexico and the United States agreed. The US 1128 submission argues that:

Article 1110(7) therefore should not be read as an element of an investor’s claim under Article 1110(1) or as a jurisdictional hook that allows a Chapter Eleven tribunal to examine whether alleged breaches of Chapter Seventeen by a NAFTA Party constitute an expropriation of intellectual property rights. Nor should Article 1110(7) be read as an invitation to review a NAFTA Party’s measures, each time they arise, for consistency with Chapter Seventeen. 87

Can an investment tribunal disregard the fact that all parties to the “contract” called NAFTA agree on its meaning? After all, it has been said that “states which are bound by [a treaty] at the relevant time, own the treaty,” which is consonant with Article 31 of the Vienna Convention, because the parties’ understanding both illuminates the “object and purpose” of the treaty and may provide evidence of the subsequent practice of the parties. 88 True, it has also

87 Eli Lilly & Co. v. Canada, ICSID Case No. UNCT/14/2, Submission of the United States of America, at 16 (Mar. 18, 2016), http://www.italaw.com/sites/default/files/case-documents/italaw7175.pdf (footnotes omitted); Eli Lilly & Co. v. Canada, ICSID Case No. UNCT/14/2, NAFTA Article 1128 Submission of United Mexican States, at 3 (March 18, 2016) (“[B]ecause of the particular role of the adjudicative power within the organization of states, Mexico agrees with Canada that, with respect to judicial acts, denial of justice is the only rule of customary international law clearly identified and established so far as part of the minimum standard of treatment of aliens . . . .”), https://www.italaw.com/sites/default/files/case-documents/italaw7174.pdf.
88 Vienna Convention on the Law of Treaties art. 31(1), May 23, 1969, 1115 U.N.T.S. 331 (entered into force Jan. 27, 1980) [hereinafter VCLT] (providing that a treaty “shall be interpreted in good faith in accordance with the ordinary meaning to be given to the terms of the treaty in their context and in the light of its purpose.”); see UNCTAD, Interpretation of IIAs: What States Can Do, IIA Issues Note, No. 3,
been argued that tribunals should ignore the parties’ views when the text is clear, also on the basis of the Vienna Convention on the Law of Treaties (VCLT), assuming of course that the meaning is clear and unambiguous from the text itself.  

The answer is that an ISDS tribunal is not formally bound by those submissions, but it should think hard and long before ignoring them. Indeed the Tribunal did pay great heed to the American and Mexican submissions. If the parties provide convincing evidence of their intention at the time of entering into the treaty, then that should have significant force because, using Vienna Convention (Article 31(1)) terminology, it provides powerful evidence of the object and purpose of the agreement. Evidence of uniform subsequent practice should also matter, and in practice it often has, in an arbitral context. This method of determining object and purpose and subsequent practice matters because even though Article 32 of the Vienna Convention allows use of “preparatory work of the treaty and the circumstances of its conclusion” as supplementary means of interpretation, an empirical analysis has shown that arbitral tribunals rarely if ever have recourse to such supplementary means, especially the travaux.

D. Lilly’s Change of Approach


92 See Iran v. United States, Case No. B1 (Counterclaim), Interlocutory Award, Award No. ITL 83-B1-FT (September 9, 2004) (“[F]ar from playing a secondary role in the interpretation of the treaties, the subsequent practice of the Parties constitutes an important element in the exercise of interpretation.”).

93 VCLT art. 32.

In its memorial, Lilly argued that, as “Robert Armitage, Lilly’s former General Counsel, explains, the utility requirement is ‘substantially harmonized across jurisdictions.’”\footnote{Eli Lilly & Co. v. Canada, ICSID Case No. UNCT/14/2, Claimant’s Memorial, at 132 (Sept. 29, 2014), http://www.italaw.com/sites/default/files/case-documents/italaw4046.pdf.} The Author’s initial report demonstrated in no uncertain terms that the harmonization argument was a red herring.\footnote{See Eli Lilly & Co. v. Canada, ICSID Case No. UNCT/14/2, Expert Report of Daniel J. Gervais, at 7–12 (Jan 26. 2015), http://www.italaw.com/sites/default/files/case-documents/italaw4139.pdf.} Every effort to agree on a definition of utility pre- and post-NAFTA, including in the patent law treaty discussions, failed to produce consensus.\footnote{See id.}

In its reply memorial to Canada’s defense, Lilly changed its approach. It abandoned the harmonization argument, even denying, despite having made it very openly as can be seen above from the mouth of its own General Counsel, that it had never claimed there had been substantive harmonization of patent law.\footnote{Eli Lilly & Co. v. Canada, ICSID Case No. UNCT/14/2, Claimant’s Reply Memorial, at 5 (Sept. 11, 2015), https://www.italaw.com/sites/default/files/case-documents/italaw4384.pdf.} One of Lilly’s experts hired in support of its reply—a former WIPO patent official—argued instead that “the industrial applicability (utility) standard is, as further discussed below, applied in a manner that is remarkably similar around the world.”\footnote{Eli Lilly & Co. v. Canada, ICSID Case No. UNCT/14/2, Expert Report of Philip Thomas, at 4 (Sept. 7, 2015), https://www.italaw.com/sites/default/files/case-documents/italaw4375.pdf.} He further noted that his “experience has also taught [him] that there are equally important areas where the practices of member states are consistent. I disagree with Professor Gervais’s attempt to place industrial applicability (utility) in the first category (of divergence) rather than the second category (of consistency).”\footnote{Id. at 12 (emphasis added).}

The Author’s second report, in reply to Lilly’s expert, quoted, inter alia, a report prepared by WIPO, indeed by the very division of which their WIPO expert was director when the report was produced.\footnote{Their expert noted in his report that “[i]n 1990, I joined the World Intellectual Property Organization (‘WIPO’) as a Senior Legal Officer. Over the next 20 years, I served in a range of senior positions, including as Director of the PCT Legal Development Division and Director of the Patent Policy Department. I retired in 2010 as Senior Director-Advisor (PCT and Patents).” Id. at 2. In his testimony} This WIPO document noted the following:

\begin{quotation}
\footnote{Id. at 12 (emphasis added).} 
\end{quotation}
Information received by [WIPO] members, reveals that there is a wide range of differences among SCP members concerning the interpretation and practice relating to the ‘industrial applicability/utility’ requirement. It also shows that the industrial applicability/utility requirement is closely linked, or sometimes overlaps, with other substantive patentability requirements, such as the sufficient disclosure (enablement) requirement, inventive step, exclusions from patentable subject matter and the definition of ‘invention’. 102

This Article lets the reader decide. Unfortunately, the Tribunal neither discussed, nor opined on, the matter of harmonization.

E. Regulatory flexibility

A significant disagreement between the parties in the Lilly case concerned the flexibility to implement international obligations. Lilly’s argument tugged directly on “the tension between the private interests of foreign investors and the regulatory autonomy of the host state.” 103 Indeed the issue of regulatory flexibility is one of the major issues in the ISDS context. This was not a case of actual or direct expropriation; instead, the notion of indirect expropriation was used to challenge the judicial application of a patent doctrine to specific inventions, thus arguably amounting to a challenge by a private non-state actor to Canada’s sovereign ability to regulate its substantive patent law and evolve its patent law through court interpretations. As noted above, investors want to limit regulatory flexibility and ISDS can provide them with a powerful tool to do so. At bottom, this becomes an argument about state sovereignty. Canada’s reply memorial noted the following in this respect:

[A]s Claimant itself acknowledges, the NAFTA Parties have flexibility in deciding how to implement the obligations of NAFTA Chapter Seventeen. Accordingly, even if NAFTA Article 1709(1) required the NAFTA Parties to impose the specific “low threshold” utility standard Claimant alleges (it does not),

---


103 Vadi, supra note 81, at 119.
it has nothing to say about how the NAFTA Parties are permitted to implement the requirement, particularly with regard to issues of evidence and disclosure.\footnote{Eli Lilly & Co. v. Canada, ICSID Case No. UNCT/14/2, Respondent’s Rejoinder on the Merits, at 65-66 (Dec. 8, 2015), \url{https://www.italaw.com/sites/default/files/case-documents/ITA%20LAW%207014.pdf} (notes omitted).}

Parties to a treaty can agree to definitions that must then be applied in the event of a dispute according to the Vienna Convention rules, but there is no definition of “utility” in either NAFTA or TRIPS. Hence, Canada was correct to argue that NAFTA left to each party “the flexibility to define and implement the specific legal standard under each of the enumerated criteria of novelty, non-obviousness or inventiveness, and utility or industrial applicability. It does not adopt any one particular meaning for any of the terms.”\footnote{Id. at 65.} Canada’s argument followed the Vienna Convention because the VCLT considers: (1) the ordinary meaning of the terms “useful” and “capable of industrial application” as understood in the patent law field in the NAFTA parties; (2) the context of Article 1709(1); (3) the subsequent practice of the NAFTA parties; (4) other relevant rules of international law; and (5) to the extent necessary to eliminate ambiguity, any relevant supplemental means of interpretation.\footnote{VCLT arts 31–32; Eli Lilly & Co. v. Canada, ICSID Case No. UNCT/14/2, Respondent’s Rejoinder on the Merits, at 66 (Dec. 8, 2015), \url{https://www.italaw.com/sites/default/files/case-documents/ITA%20LAW%207014.pdf}.} Canada argued that none of these points supports Lilly’s argument that a single or baseline notion circumscribing the meaning of utility or other patentability criteria (including those not named in NAFTA, such as enablement) bound the NAFTA parties or their domestic courts. The Tribunal agreed with Canada that ISDS tribunals were not courts of appeal of domestic courts, but noted that courts are organs of the state and that egregious errors by a court could be subject to an ISDS proceeding, thus refusing a categorical exclusion.\footnote{See Eli Lilly & Co. v. Canada, ICSID Case No. UNCT/14/2, Final Award, ¶ 221 (Mar. 16, 2017), \url{http://icsidfiles.worldbank.org/icsid/ICSIDBLOBS/OnlineAwards/C3544/DC10133_En.pdf} (“[A] NAFTA Chapter Eleven tribunal is not an appellate tier in respect of the decisions of national judiciaries.”); see also supra note 57 and accompanying text.}

In the end, all of Lilly’s claims were rejected, but the case remains relevant. First, much of the outcome relied on Lilly’s inability to provide evidence to support its case\footnote{See id. at ¶¶ 308, 349, 366, 376, 379, 385.} because the
tribunal had no difficulty accepting that patents at issue were investments.\textsuperscript{109} It also accepted that acts of courts as judicial organs of a state would be scrutinized by an ISDS tribunal—especially those that might “crystallize” an expropriation—but only if there was “clear evidence of egregious and shocking conduct” by the court.\textsuperscript{110} This means that future ISDS claims could be filed on the basis of patent invalidations. The panel also left open the possibility that a sudden change in the law might have led to a different outcome by referring to the progressive nature of the change in Canadian law—some degree of change through judicial interpretation is to be expected, particularly in a common law environment.\textsuperscript{111}

III. INTERFACES BETWEEN INTELLECTUAL PROPERTY, HUMAN RIGHTS, INTERNATIONAL TRADE & INVESTMENT

The title of this Part could easily be the title of a book. Needless to say, not every nook and cranny of the substantive interfaces between intellectual property, human rights and international trade can be explored in these pages. It gets worse: add the investment dimension and one must now square new normative and doctrinal circles. The purpose of this Part is thus only to provide the necessary context on the elements of the interface to allow this Article to make concrete doctrinal recommendations in Part V.

This Part explores the linkages between intellectual property protection in trade and investment agreements, on the one hand, and access to (at least certain) pharmaceuticals and human rights, on the other. When applied to pharmaceutical regulation the international regime in which interfaces must be built is “characterized by institutional density and governed by human rights law, international intellectual property law and international health law.”\textsuperscript{112}

A. Intellectual Property and Human Rights

\textsuperscript{109} See id. at ¶ 167 (referring to “the investments at issue in this arbitration (the Zyprexa and Strattera Patents)).
\textsuperscript{110} See id. at ¶¶ 221, 224.
\textsuperscript{111} See id. at ¶¶ 198, 310, 349.
\textsuperscript{112} Vadi, supra note 81, at 123.
The UN Charter, the texts establishing some UN specialized agencies (such as the International Labour Organization (ILO) and the UN Educational, Scientific, and Cultural Organization (UNESCO)), the International Covenant on Civil and Political Rights, the Universal Declaration on Human Rights, the European Convention on Human Rights (ECHR), and international human rights law more generally commit member states to the protection and promotion of human rights. Some core human rights are even considered *jus cogens*, creating obligations from which treaties cannot derogate. Neither intellectual property (discussed in this Section) nor the right to health (discussed in Section III.C.) are typically considered to form part of *jus cogens*.115

Some forms of intellectual property may be seen as (non-*jus cogens*) human rights when such intellectual property rights are aligned with and fulfill human rights’ objectives. This means that investors can, and do, rely on property protections or other fundamental rights in investment disputes. Infusing human rights into such disputes is this far from a one-way street.116 A first example is the right of authors in their creations while acknowledging the need for access, as required by the International Covenant on Economic, Social and Cultural Rights.117 At least part of the copyright system can be defended as a human right, for two reasons. First, because it is seen as property, and property is sometimes seen as a human right.118 Second, as René Cassin

113 Petersmann, *supra* note 21, at 32.
114 Id. at 33.
ISDS, HUMAN RIGHTS AND REGULATORY FLEXIBILITY (DRAFT)

(Nobel Peace Prize recipient (1968) and co-drafter of the Universal Declaration of Human Rights (UDHR)) noted, human beings “can claim rights by the fact of their creation.” The Charter of Fundamental Rights of the European Union also considers intellectual property as a fundamental right.

Human rights principles and analogies provide normative boundaries to the age-old quest for intrinsic equilibrium in copyright policy: the protection of interests resulting from expressed creativity, on the one hand, and the right to enjoy and share the arts and scientific advancements, on the other. Indeed, Article 27 of the UDHR is an interesting normative tool to balance copyright policy. It offers a solid justificatory theory beyond the practicalities of trade: Article 27 UDHR protects both the right to the protection of the moral and material interests resulting from and scientific, literary or artistic production of which an individual is the author and users’ right freely to participate in the cultural life of the community, to enjoy the arts, and to share in scientific advancement and its benefits. Copyright protection can thus serve to protect interests resulting from scientific, literary, or artistic production, while securing the objective of access, which is expressed teleologically as a tool to allow everyone to enjoy the arts and to share in scientific advancement and its benefits. By giving a purpose to exceptions, human rights may both serve as guidance to courts and compensate for the excessively economic focus of trade law.

120 EU Charter art. 17(2) (“Intellectual property shall be protected.”). For a discussion, see Christophe Geiger, Intellectual Property Shall be Protected!? Article 17(2) of the Charter of Fundamental Rights of the European Union: A Mysterious Provision with an Unclear Scope, 31:3 EUR. INT’L PROP. REV. 113, 113–116 (2009). (“On December 7, 2000, intellectual property (IP) entered the ‘Pantheon’ of European fundamental rights protection. . . . [T]his provision (or at least the way it seems to be understood) could contribute to amplifying the crisis of legitimacy that IP is currently facing in public opinion. For sure, IP would have been better off without this badly-drafted provision.”).
Professor François Dessemontet summarized this rather well when he wrote that “the Universal Declaration and the UN Covenant [on Economic, Social and Cultural Rights adopted on 16 December, 1966] mark the apex of the French vision of literary and artistic property, as opposed to the Anglo-American ‘mercantilist’ view as ensconced in the TRIPS.”123 Put differently, the trade-economic approach refocused copyright on the industries that produce and distribute copyrighted content. From a purely policy-oriented perspective, this ‘de-centering’ of copyright away from creators reduces the moral imperative of users, whose sympathy for large distribution multinationals (assuming for the sake of this discussion that this is a widespread perception of how the music and film industry are structured) is far from infinite.

The Lilly case was about patents, not copyrights, however, which leads to major normative differences from the copyright analysis above, as this Article will now attempt to demonstrate.

B. Patents and Human Rights

Like copyright, patents are rights to prohibit the use of protected material (works in the case of copyright; inventions in the case of patents). If seen as a form of property, they may benefit from fundamental or human right to the protection of private property. This is so even in the absence of a viable market. To that extent, they are, like other property rights, rights to exclude. Yet, as noted in the previous pages, denial of access to copyrighted material may negatively affect the human rights balance between creation and access to culture and information. Denial of patented pharmaceuticals to patients who cannot afford them, however, when they, or their government, could afford those products at a generic rate (that is, without patent rent) may be an affront to another human right, namely the right to health.124 The Preamble to the World Health Organization (WHO) Constitution provides that the “enjoyment of the

---

123 François Dessemontet, Copyright and Human Rights, in INTELLECTUAL PROPERTY AND INFORMATION LAW 113, 114 (Jan J.C. Kabel ed., 1998).

124 See Section C infra.
highest attainable standard of health is one of the fundamental rights of every human being without distinction of race, religion, political belief, economic or social condition.125

Battles between pharmaceutical companies, on the one hand, and AIDS and public health activists advocating flexibility on behalf of developing countries, on the other hand, have left scars on pharmaceutical companies, notably in the form of negative impressions on public opinion.126 Fighting public health interests perceived and presented as human rights and spokespersons, such as Médecins sans Frontières (Doctors Without Borders) and Nelson Mandela, against a backdrop of dying children to defend a “trade-related” right was a difficult public relations battle, one that should never have been waged. Moreover, an ethical, human rights approach to public health dictates limits on patent rights, especially when no real market benefit is possible because patients are too poor to afford the medication. To put it differently, no one is forcing patent holders to produce at or below cost, but patents may prevent third parties from producing lower cost versions and thus prevent availability. At its most basic level, the human rights balance argument is thus as follows: when the patent holder cannot reasonably hope to have a significant market in a territory for a product that has life-saving potential, there is no legitimate reason to prevent access to that product if someone (a public or private entity) is willing to produce it at a cost that the country can afford. There are legitimate concerns on the part of patent holders about re-exportation, and those should be adequately addressed, as they have been at the WTO.127

---

125 Constitution of the World Health Organization, Preamble, July 22, 1946, 62 Stat. 2679, 14 U.N.T.S. 185. A number of proposals have been made at the World Health Organization (WHO) not only to limit patent protection but to “delink” drug prices from the underlying R&D costs. See WORLD HEALTH ORGANIZATION, AN R&D BLUEPRINT FOR ACTION TO PREVENT EPIDEMICS 18 (2016) (“Consultations with WHO Member states highlighted that any new funding mechanism should take into account the main principles for equitable R&D . . . [including,] open knowledge innovation and delinkage of R&D costs from product price in order to ensure equitable access.”) (accessed Jan. 28, 2018).

126 See Martin L. Hirsch, Side Effects of Corporate Greed: Pharmaceutical Companies Need A Dose of Corporate Social Responsibility, 9 MINN. J.L. SCI. & TECH. 607, 632 (2008) (observing that “PhrMA may be forced to consider the negative impact that opposing human rights and consumer protection laws will have on public opinion of drug companies.”).

127 See World Trade Organization, Ministerial Declaration of 14 November 2001, ¶ 6, WTO Doc. WT/MIN(01)/DEC/2, 41 ILM 746 (2002) (commenting on the TRIPS Agreement and Public Health);
The problem of HIV infection and other severe diseases affecting the least-developed countries does not lie entirely with patents, far from it. In several African countries where patent protection would be available, antiretroviral drugs are not patented. Many others have until 2016 to adopt pharmaceutical patent protection under WTO rules. Problems often lay elsewhere, such as in the absence of a capacity of production and the lack of distribution networks. The latter can be solved, though with colossal efforts, by setting up distribution mechanisms, local clinics, etc. Concerns about interrupted treatments and the possible emergence of more aggressive viruses must be taken very seriously.

The ripple effects of the clash between patents and human rights are far from over. The WHO, for example, has actively entered the field and broadened the discussion to the entire financing of pharmaceutical research, questioning whether current models are optimal to generate “research into communicable diseases and poverty and inequity in health.” The WHO is not alone. The United Nations has generally taken a dim view of the interface between trade and human rights, especially when ISDS is factored in. A report presented in 2015 to the UN General Assembly concluded that ISDS “should be abolished as a fundamentally flawed system having adverse human rights impacts.” Ten years earlier, the High Commissioner for Human Rights offered a less radical solution, based in part on the above-mentioned references to “public morals” in GATT and GATS. The report quotes Robert Howse, who suggested that:

---


128 See Amir Attaran & Lee Gillespie-White, Do Patents for Antiretroviral Drugs Constrain Access to Aids Treatment in Africa?, 286 JAMA 1886, 1887 (2001) (“This study demonstrates that patent protection for antiretroviral drugs in Africa is not extensive.”).

129 Some commentators believe that this flexibility is “merely academic” because many sub-Saharan countries comply with TRIPS even if they are under no obligation to do so. See Poku Adusei, The Right to Health and Constitutional Imperatives for Regulating the Exercise of Pharmaceutical Patent Rights in Sub-Saharan Africa, 21 AFR. J. INT’L & COMP. L. 250, 262 (2013).


In the modern world, the very idea of public morality has become inseparable from the concern for human personhood, dignity, and capacity reflected in fundamental rights. A conception of public morals or morality that excluded notions of fundamental rights would simply be contrary to the ordinary contemporary meaning of the concept.  

On that basis, the report argued, “the exclusion of the norms and standards of international human rights on the basis of the ordinary meaning of the terms would be very difficult to sustain.” As to the meaning of “human life or health”, the report takes the view that “according to its ordinary meaning, is also very broad and has considerable potential to include a number of human rights. Certainly, the right to life and right to health fall within its scope.”

C. The “Right to Health” in Context

In what is perhaps its clearest articulation, the right to health appears in Article 12 of the International Covenant on Economic, Social and Cultural Rights (ICESCR), which recognizes “the right of everyone to the enjoyment of the highest attainable standard of physical and mental health.” According to General Comment 14, this right to health requires access to at least certain medicines. The right also rests on Article 25.1 of the 1948 Universal Declaration of Human Rights:

Everyone has the right to a standard of living adequate for the health and well-being of himself and of his family, including food, clothing, housing and medical

---


134 OHCHR Report, supra note 132, at 5.

135 Id.

136 ICESCR, supra note 117, at art.12.

care and necessary social services, and the right to security in the event of unemployment, sickness, disability, widowhood, old age or other lack of livelihood in circumstances beyond his control.\footnote{G.A. Res. 217 (III) A, Universal Declaration of Human Rights (Dec. 10, 1948).}

The IP/pharmaceutical patent protection relation with this “right to health” appears to dominate much of the discussions. Normatively, it is the hypotenuse of the IP/pharmaceutical/human right (to health) triangle mentioned in the opening paragraph of this Part. It is not just about providing property-like rights to pharmaceutical research companies. As Valentina Vadi notes, pharmaceutical protection reflects both private and public interests, namely the private interest of the patent owner (that is, exclusive rights for the term of the patent and possible extensions), but also the public interest.\footnote{Vadi, supra note \textit{77}, at 121.} The public interest is protected by access to (new) life-saving or life-improving medicines, of course, and that is a fundamental part of the bargain. But the public interest is also served by the possibility (afforded by the patent disclosure) for other innovators to build on inventions disclosed to develop their own, including in markets where no patent is in force and in which there is thus no need to wait for the expiration of the patent.\footnote{See id. On the value of patent information, see Sean B. Seymore, \textit{The Teaching Function of Patents}, 85 NOTRE DAME L. REV. 621, 661 (2010) (suggesting an improvement in patent documentation because “[a] more technically robust patent document, replete with working examples, will allow follow-on innovators to more easily and quickly create second-generation products and processes.”); and Lisa Larrimore Ouellette, \textit{Do Patents Disclose Useful Information?}, 25 HARV. J.L. & TECH. 545, 601 (2012) (noting that “the technical value of patent disclosures is greater than many legal scholars have appreciated, but also that many patents probably fail to meet the existing disclosure requirements.”).} Indeed, while there are real debates about the net (in aggregate) positive impact of patents on innovation writ large, empirical studies tend to isolate pharmaceuticals as an area in which they produce positive outcomes.\footnote{Outside the pharmaceutical and chemical industries, James Bessen and Michael Meurer “safely conclude that during the late 1990s, the aggregate cost of patents exceeded the aggregate private benefits of patents for United States public firms.” \textit{JAMES BESSEN & MICHAEL J. MEURER, PATENT FAILURE: HOW JUDGES, BUREAUCRATS, AND LAWYERS PUT INNOVATORS AT RISK} 141 (2008). The classic study might still be Edwin Mansfield, \textit{Patents and Innovation: An Empirical Study}, 32 MGMT. SCI. 173, 174 (1966).}

How does this nuanced grouping of private and public interests translate into trade rules? Such rules can accommodate at least some of the triangular policy equation outlined in the previous paragraphs, as the adoption of the Ministerial Declaration on TRIPS and Public Health...
and the subsequent 2003 establishment of the “paragraph 6 system” at the WTO illustrate. The issue that arises not in trade, but in an ISDS context, however, is the singular focus on the protection of private interests. This casts a deep shadow over the public interest component built into the patent system, thus potentially creating a severe policy imbalance. Put differently, in a state-to-state dispute settlement context, such as at the WTO Dispute-Settlement Body (DSB), public policy arguments can and are regularly used to justify (e.g., under general exceptions clauses in GATT or GATS) a prima facie violation of a trade-related commitment contained in a WTO instrument.

Does the same reasoning apply to ISDS? Professor Sornarajah suggests that conflicts between private and public interests are likely to be structurally prevalent in ISDSDue to the use by panels of “low-order sources of international law like decisions of tribunals and the writings of ‘highly-qualified publicists’ who are no more than hired guns” thus not leaving states to address “issues involving economic development, poverty, welfare needs [and] the environment.” Kate Myles suggests in the same vein that there is “little room for the consideration of the public interest in a regime so heavily weighted towards investor protection.” If patents are seen as property, then their revocation, even where fully justified under domestic law, may appear at first glance like an expropriation, absent the broader normative context that typically informs patent and innovation policies.

142 See B. K. Baker & K. Geddes, supra note 50, at 28 n.127.
143 See Vadi, supra note 81, at 146.
144 In the specific case of intellectual property a WTO dispute-settlement panel discussing TRIPS Article 8 noted the following: “This fundamental feature of intellectual property protection inherently grants Members freedom to pursue legitimate public policy objectives since many measures to attain those public policy objectives lie outside the scope of intellectual property rights and do not require an exception under the TRIPS Agreement.” Panel Report, European Communities—Protection of Trademarks and Geographical Indications for Agricultural Products and Foodstuffs, ¶ 7.210, WTO doc. WT/DS174/R (Mar. 15, 2005).
145 Muthu-Cumaraswamy Sornarajah, Evolution or Revolution in International Investment Arbitration? The Descent into Normlessness, in EVOLUTION IN INVESTMENT TREATY LAW AND ARBITRATION (Chester Brown & Kate Miles eds., 2011), 631, 655-6.
146 Kate Myles, Reconceptualizing International Investment Law: Bringing the Public Interest into Private Business, in INTERNATIONAL ECONOMIC LAW AND NATIONAL AUTONOMY 295, 296 (Meredith Kolsky Lewis & Susy Frankel, eds., 2010).
Professor Susy Frankel notes in connection that:

Investment tribunal arbitrators when making decisions (including the interpretation of the agreements at issue) are likely to focus on the function of IP as a set of property rights rather than as equally important parts of the international IP structure, which enables tailoring of those rights to reward innovation appropriately (rather than excessively) and to maintain regarding interests, such as when property rights need to be balanced with affordability and availability of medicines . . . . [T]hat does not require and should not result in detaching the property aspects of IP from its other functions and objectives. 147

True, “property” in the patent field does not mean quite the same thing as, say, in real estate, even if all property rights arguably have a societal function. 148 For example, property rights are sometimes described as absolute. 149 Intellectual property by contrast has inherent limitations (e.g., term) and exceptions (e.g., fair use) built into the system. They are “part of the framework of rights, rather than being something that gnaws away at them.” 150 Those broader societal objectives related to innovation and access provide “both boundaries and the framework of the scope of the property rights.” 151

Then the grant of a patent right has a specific purpose, and that purpose, seen teleologically (from a policy perspective), is primarily an instrument to create an incentive that will be in the (private) interest of the patent holder but for the greater public interest in access to innovation. 152 The public interest component present, to a certain extent at least, in state-to-state


148 See Jakob Cornides, Human Rights and Intellectual Property: Conflict or Convergence?, 7 J. WORLD INT’L PROP. 135, 143 (2004) (“[P]roperty is not an end in itself. Obviously, it must be used in a way that contributes to the realization of the higher objectives of human society.”).

149 See generally Robert P. Burns, Blackstone’s Theory of the “Absolute” Rights of Property, 54 U. CIN. L. REV. 67, 72 (1985) (“Of all the absolute rights, the most essential are those of personal security, personal liberty, and private property.”)

150 Frankel, supra note 147, at 14.

151 Id. at 16.

152 See Christophe Geiger, The Social Function of Intellectual Property Rights, or How Ethics Can Influence the Shape and Use of IP Law, in MAX PLANCK INSTITUTE FOR INTELLECTUAL PROPERTY AND COMPETITION LAW, Research Paper No. 13-06 (2013), at 12 (“Society has a need for intellectual productions in order to ensure its development and cultural, economic, technological and social progress and therefore grants the creator a reward in the form of an intellectual property right, which enables him to exploit his work and to draw benefits from it. In return, the creator, by rendering his creation accessible
dispute settlement is not the same when a party to the dispute is a multinational company. As Susan Sell notes, despite all the rhetoric of economic competitiveness, states are not firms.153 Firms “only have to worry about one thing—shareholder value. The bottom line is always to earn a profit, and they have one clear goal—to increase shareholder value. Policymakers face a much more complicated array of issues and priorities.”154 Yet, as noted above, patent holders use human rights, such as private property protection in their favor.155

Still, patent owners using ISDS to challenge regulatory measures adopted by host states can directly impact regulatory autonomy, including the state’s ability to make and change innovation policies and to protect human rights.156 Hence, the risk is that allowing ISDS to interpret the scope of intellectual property obligations as private property and well beyond issues of actual expropriation “stand to disrupt regulations governing everything from public health, energy, finance, education, privacy, and free expression. Under these provisions investors can attack domestic social bargains and, if successful, override legitimate sovereign regulatory discretion.”157 As far as evolution of the law in court opinions are concerned, the Tribunal in the Lilly case found that such evolutions were normal and that investors should expect them to happen.158

The potential conflict between ISDS and human rights exacerbates the risk that tenuous bridges built to allow states to enforce human rights when those rights conflict with trade commitments will collapse. The chink in the post-Westphalian armor is that supranational mechanisms meant to cabin states to avoid bad actions may be used to prevent them from performing good ones. Although this claim could be made with respect to trade law—especially

154 Id. at 318.
155 See supra Section III.A.
156 See Vadi, supra note 77, at 186.
157 Sell, supra note 153, at 317.
158 See Eli Lilly and Co. v. Gov’t Canada, ICSID Case No. UNCIT/14/2, Final Award, ¶¶ 198, 310, 349 (Mar. 16, 2017), http://icsidfiles.worldbank.org/icsid/ICSIDBLOBS/OnlineAwards/C3544/DC10133_En.pdf.
with the more powerful WTO DSB (compared to its GATT predecessor)—direct conflicts have thus far been reasonably well handled—often by avoidance.\textsuperscript{159} In the ISDS context, the question that arises is, when such conflicts emerge, how will they be handled?

The arc of trade law is moving in a positive direction, towards at least conflict avoidance and perhaps even some form of reconciliation. Professor Helfer has offered a vision of interpenetration and cross-pollination of intellectual property and human rights, possibly even a form of integration.\textsuperscript{160} Will ISDS go in the opposite direction? As Professor Okediji commented, this is a “stunning change” as she noted that the Lilly case represented “uncharted territory in the increasingly complex and contested landscape of international intellectual property obligations.”\textsuperscript{161} In her view, national innovation policy is:

\begin{quote}
[O]ne of the very few areas still largely insulated from the pervasive economic governance that conditions contemporary international economic relations. Intellectual property obligations in the investment context thus pose a new threat to states’ traditional lawmaker powers by providing foreign actors a singular opportunity to challenge laws that have been enacted with the domestic public interest in full view.\textsuperscript{162}
\end{quote}

Professors Dreyfuss and Frankel have noted (rightly in this Article’s view,) along similar lines, that the TRIPS Agreements may contain upper limits to justify limits on intellectual property in the public interest, such as those contained in Articles 1.1, 7 and 8 of the TRIPS Agreement.\textsuperscript{163} Those are for the most part absent from NAFTA and many other IIAs.\textsuperscript{164}

\textsuperscript{159} The GATT was weaker because a losing party could veto adoption of the report. Not so under the WTO. See supra note 25.


\textsuperscript{161} Okediji, supra note 57, at 1122.

\textsuperscript{162} Id.

\textsuperscript{163} Rochelle Dreyfuss & Susy Frankel, From Incentive to Commodity to Asset: How International Law is Reconceptualizing Intellectual Property, 36 MICH. J. INT’L L. 557, 588 (2015) (“While the Basic Principles of the TRIPS Agreement permit states to implement more extensive protection, there is a proviso: they may not go so far as to ‘contravene the provisions of the Agreement.’ Now that it is clear how easily theories of commodification and assetization can unravel the rationale behind IP protections, the proviso could play a more prominent role in the future. The Objectives provision of TRIPS recognizes that IP protection should be to the mutual advantage of producers and users, create a balance of rights and obligations, and promote technical transfer. Thus, agreements that undermine those objectives should not be regarded as legitimately made.”).

\textsuperscript{164} Id.
In sum, regulatory autonomy in the public health area is constrained by trade law, but only to a limited extent because, as the next Part explicates, doctrinal interfaces exist to factor in the public interest and human rights in trade disputes. In the ISDS context, that regulatory autonomy may be threatened due to the very fuzzy interface with both human rights law and regulatory autonomy. Panels in ISDS disputes can and often do consider human rights arguments put forward by a party as they would any other argument brought to their attention. Is that a sufficient guarantee? The answer is certainly not a clear yes.

Protecting human rights can be seen in this context as a subset of a broader regulatory regime protecting social welfare and other key public policy objectives. The challenge is to integrate regulatory autonomy and the public interest that underpins it into the ISDS equation, a task to which the last Part now turns its attention. Before doing so, let us see which interfaces have been used in the area of trade law and whether they can be ported to the ISDS context.

IV. DOCTRINAL INTERFACES

A. Balancing Human Rights, Trade and Investment

There is no recognized supremacy or hierarchy of human rights and trade and investment rules—at least beyond jure cogens. General principles of interpretation apply, however. Hence, one may argue that an IIA signed after the conclusion of an instrument protecting human rights may have priority under the lex posterior derogat legi priori canon, or that an IIA should take precedence over more general human rights obligations under the lex specialis derogat legi generali canon.

The WTO Dispute Settlement Body (DSB) uses the VCLT and “general balancing principles (such as transparency, non-discrimination, necessity, and proportionality) in deciding on whether national restrictions of freedom of trade are necessary for the protection of public

---

164 The text of NAFTA chapter 17 contains no equivalent provision. NAFTA, supra note 2.


166 Petersmann, supra note 21, at 33. According to the lex posterior derogat (legi) priori canon, a later law prevails over an earlier one. According to the lex specialis derogat legi generali canon, a more specific law prevails over a general one.
DSB reports often limit the scope of their review of WTO Members’ regulatory autonomy. This raises directly the interface question: can a WTO Member use an obligation to comply with its human rights obligations to derogate from a trade commitment, absent a direct possibility to do so in the text containing the commitments? Professor Pauwelyn, for example, has advocated allowing:

[T]he use of human rights as a defence against a claim of WTO violation in WTO dispute settlement but only if (i) both disputing parties are bound by the human rights provision in question, (ii) there is an irreconcilable conflict between the WTO obligation, on the one hand, and the human right, on the other, and (iii) pursuant to a conflict clause in either treaty or the applicable conflict rules of public international law (eg, lex posterior or lex specialis), the human rights provision prevails over the WTO provision.

The WTO Appellate Body has not articulated this interface quite that way. Professor Petersmann, opining on the dispute on Australian plan packaging legislation, suggested a more flexible balancing:

Just as national courts tend to “balance” economic and health rights on the basis of constitutional principles of non-discrimination, good faith, necessity and proportionality of governmental restrictions, also regional and WTO dispute settlement jurisdictions must interpret IEL “in conformity with principles of justice” and “human rights and fundamental freedoms” as accepted by all WTO members, notwithstanding the fact that the differences among the applicable laws in different jurisdictions may entail different procedures (e.g. regarding burden of proof, judicial standards of review) and legitimately different interpretations of HRL, constitutional laws, health law and IEL. The WTO panel [in the plain packaging case] should therefore repeat and clarify in respect of the TRIPS Agreement what the Appellate Body has already indicated with regard to the TBT Agreement, i.e. that the legal and judicial “balancing methods” for interpreting the specific WTO agreements should proceed from the same “principles of justice”

---

167 Id. at 34.

168 See Petersmann, supra note 166, at 34.

169 This possibility is explored in Part V.


171 Id. at 210.
underlying WTO law as well as the human rights obligations of WTO members.\(^{172}\)

Other commentators balk at the thought of having human rights obligations taken on board in trade tribunals, fearing a “take over” of human rights by trade law.\(^{173}\)

Like the WTO DSB, ISDS tribunals apply the VCLT. This suggests that the arguments used to support the VCLT-based approach to human rights and balancing tests used in trade may port to the investment area, if credible and useful parallels can be established.\(^{174}\)

B. Incorporating Human Rights in Trade and Investment Disputes

An option to operationalize the interface between human rights, on the one hand, and international trade and investment law, on the other hand, is the incorporation or integration of (specific) human rights in the trade or investment regime itself. Such an integrative approach can be pushed quite far, as one sees in the work of Professor Petersmann, for example. He argued (in the case of trade) that free trade forms part, or at least is aligned with, the international human rights framework, in particular in advocating respect for human dignity, individual autonomy, and the free development of one’s personality through enterprise or business.\(^{175}\) Free trade can help an “individual’s right to trade the fruits of her labour in exchange for foreign goods and services needed for personal self-development in dignity.”\(^{176}\) Petersmann’s view, anchored in Kant’s idea that a constitutional law doctrine of fundamental rights and duties of citizens could


\(^{173}\) See lston, *supra* note 4, at 837 (“noting that the WTO is not “designed, structured, or suitable to operate in the way that [an institution] with major human rights responsibilities would.”)


\(^{176}\) Id. at 26.
also apply internationally,\(^{177}\) is that GATT and other international trade rules, typically viewed as policy instruments designed to improve access to foreign markets, should also be viewed as “domestic policy instruments that could serve not only economic functions (e.g., for promoting economic welfare), but also ‘constitutional functions’ (e.g., by rendering domestic constitutional principles of freedom, non-discrimination, rule of law, and judicial review more effective in the trade policy area).”\(^{178}\) In his critique of this approach Professor Alston notes that the subset of rules enshrined in international trade law are not those that are “recognized as economic rights within the framework of international human rights law.”\(^{179}\)

This debate can be neither resolved nor even fully investigated here. Whether or not it is correct to assert that free trade meshes with the international human rights framework, however, the idea that a “constitutional” approach advocating not just a rapprochement between human rights and trade (possibly adding investment), forms the basis for a doctrinal interface worthy of a bit more exploration. Indeed, this might explain why the “currency [of this approach] has persisted,” in spite of harsh criticism both in academia and by developing countries.\(^{180}\)

How one defines constitutionalism is often infused with the view one takes of the positive/natural law debate.\(^{181}\) In a model of liberal constitutionalism, “the constitution establishes a set of electoral rules, and distributes capacities and functions among governmental institutions.”\(^{182}\) In a different model, such as the United States, a constitution adds “a layer of

---


179 Alston, *supra* note 4, at 822 (emphasis added).

180 See Deborah Z. Cass, *The ‘Constitutionalization’ of International Trade Law: Judicial Norm-Generation as the Engine of Constitutional Development in International Trade*, 12:1 EUR. J. INT’L L 39, 40 (2001) (“[E]ven after it became apparent that the claim was considered provocative not only by the trade law establishment, but also by developing countries and non-governmental organizations with interests ranging from business regulation through environmental standards, to labour reform.”).

181 What I mean here, in very succinct fashion, is that a constitution is a highest norm in Kelsen’s theory but there are higher organic norms in a natural law approach.

This typically limits what (each level of) government can do, either by granting exclusive power over a certain area to one level of government (thereby excluding others) or by imposing a set of “higher” rules and principles (such as those contained in the US Bill of Rights or the EU Charter). Typically, governments cannot (easily) derogate from such rules and principles—acknowledging at the same time that enforcement is key. Consequently, the existence of words describing such rights in a constitutional text does not always mean that they will be applied to preserve the liberties of individual citizens.184

A constitutional approach allows one to link higher-level norms at the domestic level and international norms, such as customary international law. For example, the Restatement (Third) of the Foreign Relations Law of the United States notes that “there is a willingness to conclude that prohibitions [against human rights violations] common to the constitutions or laws of many states are general principles that have been absorbed into international law.”185 As used in the context of international trade, “constitutionalizing” might thus be translated as promoting “an increasing ‘internationalization’ of formerly domestic constitutional law concepts (like non-discrimination, necessity, and proportionality of government restrictions on transnational trade).”186 Used in this sense “constitutionalization” of trade law is an approach that can add normative depth to treaty interpretation, in part because it can broaden the range of interpretive tools.

How would such an approach work in an ISDS context? The answer is far from clear. Investor-state is not about free trade; it is about investment and “property” protection.187

---

183 Id. at 21 (“Guatemala, Iran, the Soviet Union and various authoritarian regimes elsewhere have had wonderfully worded bills of rights that produced no discernible increase in respect for individual liberties in those countries.”).


187 See Alvarez, supra note 116.
the indirect expropriation argument applied to a very specific type of “property,” however, Lilly’s complaint challenges the criteria used by domestic courts, after due process, to decide that two patents were invalid. To argue that invalidation is a violation of the patent owner’s human rights (protection of property) is a huge step, one that this Article refuses to take. This explains why a constitutional approach seems risky in an ISDS context. Alston’s critique of a possible normative and institutional takeover of human rights by trade law and trade tribunals resonates louder here than in trade, even if at least some aspects and normative underpinnings of international trade law are aligned with a number of economic and developmental human rights. In an ISDS context, by contrast, if a clash between investment protection and human rights emerges, the “supreme” value of investor and property protection may be a poor sextant to arbitrate the place of human rights if the normative lodestar is the rights of multinational investors. In sum, although private property protection is consistent with human rights, it is one of many such rights that should be considered in that context.

C. Contractarian approaches

Contract-based approaches have been suggested to broaden the scope and nature of norms that international trade tribunals can use to interpret trade agreements. This seems particularly relevant in an ISDS context because a significant part of the IIAs, namely the BIT regime, “was developed on the basis of a contractual way of thinking, lifting contractual claims out of a domestic context and into an international law context.” Put differently, ISDS is perhaps best seen as private law while trade law as public law.

1. Filling normative lacunae

---

188 See supra Part II.A.

189 See supra note 4 and accompanying text.

190 See Alvarez, supra note 116.

191 MOUYAL, supra note 165, at 223 (emphasis in original). The book only briefly mentions public health, see id. at 217–218, and NAFTA, see id. at 68–73, but constitutes a most helpful study of the general interface between human rights and investment law, including a detailed list of extant BITs and model BITs. See id. at 223.
Any court interpreting a legal text, whether a contract, statute or treaty, may be called upon not just to interpret it, but also to fill lacunae.\(^{192}\) Lacunae may be said to exist for several reasons, including that terms are left undefined; that definitions they contain are unclear; or that there are missing elements and interstices in the texts. In the case of a treaty specifically, this includes taking account of relevant rules of international law, as provided in the VCLT.\(^{193}\)

 Depending on the issue, international law can both provide context and constitute “relevant rules of international law applicable in the relations between the parties.”\(^{194}\)

As was done for constitutional approaches, let us see first how this applies in the trade law context. Non-WTO international agreements may provide context to interpret the provisions of WTO agreements, as the WTO Appellate Body did in the Shrimp-Turtle case.\(^{195}\) Using external norms as interpretive tools can be done without making law, which panels and the Appellate Body are prohibited from doing under the DSU.\(^{196}\)

As the International Law Commission suggests, international law can “supplement” WTO law, unless the opposite is explicitly stated in the agreement.\(^{197}\) Along similar lines, in its 2008 resolution No. 5/2008 on International Trade Law the International Law Association declared that “WTO members and bodies are legally required to interpret and apply WTO rules

\(^{192}\) A lacuna in a specific treaty does not mean a lacuna in international law, in the sense that international law beyond the text of the treaty can “fill” the lacuna. See Prosper Weil, “The Court Cannot Conclude Definitively ...” Non Liquef Revisited, 36 COLUM. J. TRANSNatl. L. 109, 10 (1997).

\(^{193}\) This often amounts to “interpreting silence” to quote the term used by Lone Wandahl Mouyal in this context. MOYAL, supra note 165, at 54.

\(^{194}\) VCLT, supra note 88, arts. 31(1) and 31(3)(c).


\(^{196}\) DSU Article 3(2) provides: “The dispute settlement system of the WTO is a central element in providing security and predictability to the multilateral trading system. The Members recognize that it serves to preserve the rights and obligations of Members under the covered agreements, and to clarify the existing provisions of those agreements in accordance with customary rules of interpretation of public international law. Recommendations and rulings of the DSB cannot add to or diminish the rights and obligations provided in the covered agreements.” See also Susy Frankel & Daniel Gervais, Plain Packaging and the Interpretation of the TRIPS Agreement, 46 VAND. J. TRANSNAT'L L. 1149, 1206 (2013).

in conformity with the human rights obligations of WTO members under international law.”

Then, as was pointed out by the International Court of Justice (ICJ):

> It being the duty of the Court itself to ascertain and apply the relevant law in the given circumstance of the case, the burden of establishing or proving rules of international law cannot be imposed upon any of the parties for the law lies within the judicial knowledge of the Court.

It is often noted in this regard that the Appellate Body has said that WTO norms are not to be read in “clinical isolation” from international law. The WTO is not part of the United Nations and, although its former Director General Supachai Panitchpakdi “affirmed the vital importance” of the UN Millennium Development Goals (MDGs), including the goal to combat HIV/AIDS, malaria and other diseases, those goals were not formally incorporated into the WTO framework. The closest reference one can point to might be that contained in the TRIPS Declaration on Public Health, adopted in 2001, approximately one year after the Millennium Summit in September 2000 at which the MDGs were adopted.

At least two contract-based theories have been offered to suggest how trade tribunals should use the VCLT. Some suggestions are infused with normative objectives, such as Professor Harris suggestion that the WTO Appellate Body “may nevertheless take the Agreement's unfairness into account by using the treaty of adhesion doctrine to interpret its

---

198 Int’l Law Ass’n Res. No. 5/2008 (Aug. 17–21, 2008). Under its Constitution, the International Law Association (ILA) is an international non-governmental organisation has consultative status. Its objectives are “the study, clarification and development of international law, both public and private, and the furtherance of international understanding and respect for international law.” International Law Association, Constitution of the Association art. III, §1.


provisions more favorably to developing countries.” The WTO has a number of special and differential provisions (including in the DSU) and it is unlikely that such a normative overlay will be applied in the context of a dispute absent support in a negotiated text, whether that be a WTO-negotiated agreement or a ministerial or decision. The second is the doctrine of incomplete contracts, on which we now turn the spotlight.

2. Incomplete contracts

In the wake of Hadfield’s suggested application of the incomplete contracts theory to statutes, Joel Trachtman suggested that WTO panels and the Appellate Body could do the same to treaties, though not without significant constraints and difficulties. He pointed to the role of adjudication bodies, especially when interpreting standards instead of rules. A standard is not a lacuna; it needs to be interpreted and applied to a specific fact pattern, however. As Trachtman explained, “[l]acunae are circumstances where there is no law and no constraint. This is quite different from a standard, where there is law applicable by a dispute resolution tribunal but less explicit guidance to the tribunal as to how to decide.”

Now let us see how this might apply in an ISDS context. As already noted, arbitral tribunals operating in an ISDS context follow the VCLT in interpreting investment treaties (or investment chapters of trade agreements). The Lilly Award makes a very interesting series of points in that regard:


204 See Mary Sabina Peters & Manu Kumar R, Annotation, *Introspect "Special and Differential Treatment" Given to Developing Countries Under the WTO Dispute Settlement System, 17:6 A.L.R. Int’l 123, 124 (2014) (“[T]he DSU included some provisions that referred to developing countries’ special needs. However, these Special and Differential Treatment (SDT) measures have turned out to be of very limited value to developing countries . . . Most of the clauses in DSU regarding developing countries have turned out to be declarative rather than operative.”).


207 Id. at 376.

208 See *supra* note 174 and accompanying text.
The phrase “applicable rules of international law” addresses not simply, for example, rules of interpretation of treaties, such as those reflected in Articles 31 and 32 of the Vienna Convention on the Law of Treaties ("VCLT"), but also any other applicable rules of international law that may be relevant to the case before it. . . . It will be a matter for each tribunal constituted under Section B of NAFTA Chapter Eleven to evaluate, with the assistance of submissions of the parties on the matter, the precise scope of the phrase “applicable rules of international law” in the circumstances of the case of which it is seised.209

The VCLT directs tribunals to consider the plain meaning of the text. Yet, as the arbitral tribunal pointed out in Saluka v. Czech Republic, the VCLTs direction about object and purpose is also key in interpreting the scope of obligations, and it includes both an immediate and a broader context.210 Because they do follow the VCLT, ISDS panels thus consider the plain meaning of the text in light of its object and purpose, and the subsequent practice of the parties in its application.211

True, it may be difficult to argue before an ISDS tribunal that it must consider human rights texts because an investment treaty (or the investment chapter of a trade treaty like NAFTA) is “incomplete.” Yet, the conflict between the object and purpose of the investment chapter (to protect property) and the object and purpose of the IP chapter of an IIA (forming part of a balanced and effective innovation policy) must be reconciled. Petersmann suggests a balancing test similar to his proposal in the WTO context:

Investment arbitral tribunals should likewise aim at reconciling the general principles of law underlying the almost 3,000 investment treaties with the governmental duties to protect public health not only on the basis of the specific treaty commitments, but also with due regard to the progressive judicial


210 Saluka v. Czech Republic, Partial Award, at 66–67 (Perm. Ct. Arb. 2006), http://www.italaw.com/sites/default/files/case-documents/ita0740.pdf ("The ‘fair and equitable treatment’ standard in Article 3.1 of the Treaty is an autonomous Treaty standard and must be interpreted, in light of the object and purpose of the Treaty . . . . In applying this standard, the Tribunal will have due regard to all relevant circumstances."). This tribunal operated under UNCITRAL Rules, as did the one in the Lilly case. See supra note 50.

211 Arbitral tribunals are not bound by the parties’ statements about their intention when entering into the agreement and tend not to pay much attention to the travaux. See supra notes 51–53, and accompanying text.
ISDS, HUMAN RIGHTS AND REGULATORY FLEXIBILITY (DRAFT)

clarification of their underlying “principles of justice” acknowledging sovereign rights to give priority to existential public health values over utilitarian justifications of trade and investment law.\textsuperscript{212}

This opens a door for an ISDS tribunal to bring human rights and other key public policy objectives in its analytical mix, especially in cases where the specific solutions proposed in the last Part of this Article have not been applied to the applicable IIA.

3. Stipulation for Another

Another contract-based approach reflects the fact that investor-state mechanisms contained in investment treaties between two or more states (or the investment chapter of a trade agreement) are not for the benefit of any of the parties to the “contract.” This doctrinal mechanism is specific to the ISDS context and, hence, there is no need to compare its application in the trade and investment realms.

ISDS is arguably what French law calls a “stipulation pour autrui” (“stipulation for another”), which French law defines as follows:

There is stipulation for another where, in a contract, one of the parties, called the stipulator, stipulates to the other, called the promisor that the latter shall give or do something for the benefit of an extraneous third party, the beneficiary who thereby becomes a creditor without having been a party to the contract.\textsuperscript{213}

While theoretically prohibited in French law, there are many cases in which such stipulations are allowed.\textsuperscript{214} In a common law context, establishing a third party right of suit in a contract may be said to offend the privity of contract. Privity implies that “a third party cannot be subjected to a burden by a contract to which he is not a party,” but this does not fully answer the

\textsuperscript{212} Petersmann, supra note 172, at 65.


\textsuperscript{214} Humphreys and Higg, supra note 212, at 466. The German civil code (BGB) “provides explicitly in § 328 that a contract may be made for the benefit of a third party, thus giving the third party a right to demand performance.” Fabrizio Cafaggi, The Regulatory Functions of Transnational Commercial Contracts: New Architectures, 36 FORDHAM INT’L L.J. 1557, 1595 (2013); see also Hendrik Verhagen, Contemporary Law, in CONTRACTS FOR A THIRD PARTY BENEFICIARY: A HISTORICAL AND COMPARATIVE ACCOUNT 137 (Jan Haliebeek & Harry Donkor eds., 2008).
question whether allowing a third party to benefit from the contract, may imply, if the third party chooses to accept this benefit, also an obligation on that third party.\textsuperscript{215} A privity-based approach has been applied in a treaty context in asking, for example, whether Paris Club practice of not requiring the rescheduling of bilateral obligations to the International Monetary Fund and the World Bank creates a right to sue for the Fund and the Bank.\textsuperscript{216} It is also reflected in the VCLT itself, which provides both that “[a] treaty does not create either obligations or rights for a third State without its consent,” and that a “right arises for a third State from a provision of a treaty if the parties to the treaty intend the provision to accord that right either to the third State . . . and the third State assents thereto.”\textsuperscript{217} At common law, third party beneficiary status arises “when parties make a valid contract which contains provisions evidencing a clear intent to operate for the benefit of the third party.”\textsuperscript{218}

This is not radical thinking. If A sells her house to B, but stipulates that C can live in part of the house if C pays rent, then C can “trigger” the right to live in the house, but has the corresponding obligation to pay rent. Similarly, if D takes insurance for E’s benefit, then the insurance company can claim unpaid premiums from E before paying the benefit. Article 5.2.1 of the International Institute for the Unification of Private Law’s (UNIDROIT) Principles of International Commercial Contracts provides a rule for contracts in favor of third parties, which states in part that the “existence and content of the beneficiary’s right against the promisor are determined by the agreement of the parties and are subject to any conditions or other limitations.


\textsuperscript{216} Martha Rutsel Silvestre J., \textit{Preferred Creditor Status under International Law: The Case of the International Monetary Fund}, 39 INT’L & COMP. L. Q. 801, 815–16 (1990) (noting also that “[w]ith respect to the law of treaties the view has been taken that the beneficiary of a ‘stipulation pour autrui’ can only in the case of an actual right invoke directly and on its own account the provision conferring the benefit.”).

\textsuperscript{217} VCLT, supra note 88, art. 34, art. 36 \& I. See also Jimenez de Arechaga, \textit{Treaty Stipulations in Favor of Third States}, 50 AM. J. INT’L L. 338, 356 (1956).

\textsuperscript{218} William C. Walter and Michael V. Cory Jr., \textit{The Circumvention of Mississippi’s Prohibition of Direct Actions}, 66 MISS. L.J. 493, 501 (1997). For example, in my Law School’s jurisdiction (Tennessee) “the requisites necessary to establish a third party beneficiary relationship are: (1) a valid contract made upon sufficient consideration between the promisor and promisee; and (2) the clear intent to have the contract operate for benefit of a third party.” United Am. Bank of Memphis v. Gardner, 706 S.W.2d 639 (Tenn. Ct. App. 1985) (citations omitted).
under the agreement.\textsuperscript{219} The Comment to this Article notes in this respect that “the promisor and promisee enjoy broad powers to shape the rights created in favour of the beneficiary.”\textsuperscript{220}

Would it be conceivable to use this notion to suggest that corporations using ISDS must comply with certain obligations? This is a possibly fruitful dimension to explore further. Providing corporations with a right to sue states under an IIA implies that corporations have a legal personality at international law. The argument one could make is that this attribution of legal personality comes with a very important right (to sue states in a separate tribunal), but it could also imply certain obligations, including upholding human rights.\textsuperscript{221} Put differently, if a corporation gets personality and the right to sue, can the sued state demand compliance with any international obligations, as it could against the state where the corporation is established? Enforcement of human rights violations against multinational corporations is not unheard of: parallels have been drawn in that context to the Alien Tort Statute.\textsuperscript{222}

As Professor Alzarez observed in that respect:

Under investor-state arbitration, therefore, states are mostly passive participants in a game controlled by corporate plaintiffs in which the latter play the


\textsuperscript{220} Id. at 163.

\textsuperscript{221} Glen Kelley, Multilateral Investment Treaties: A Balanced Approach to Multinational Corporations, 39 COLUM. J. TRANSNAT'L L. 483, 527 (2001) (“[I]n the Reparations Case the International Court of Justice found that the United Nations enjoyed international legal personality but did not have the same rights and duties as a state under international law. This principle of limited international legal personality could be applied to MNCs as well. A duty for MNCs to uphold selected human rights, created by an investment treaty, would be enforceable by states under international law without expanding the rights of MNCs under international law.”) (notes omitted).

jurisgenerative role that in the WTO and throughout much of international law is formally reserved to states. Most BITs and FTAs explicitly provide investors with the ability to pursue their claims vis-à-vis states at the international level. To the extent the ICJ concluded in the Reparation Case that the ability to act as a person is the principal determinant of personhood status, the same conclusion can even more readily be drawn with respect to corporations and other investors under the international investment regime.  

In sum, contract-based approaches can, in keeping with the VCLT, provide a means to fill gaps in texts by using international norms not contained in the text but part of the context at the time of its establishment, or relevant to the parties for other reasons, including subsequent practice. A stipulation pour autrui/privity doctrinal approach goes a step further and allows one at least to ask whether corporations meant to be the beneficiaries of ISDS may also, when given the right to sue states, have certain obligations. In contrast, efficient breach does not seem a promising way forward. In Part IV, the notion of obligations imposed on corporations will form part of the discussion on ways forward.

D. Express Interfaces

1. Trade

IIAs can and often do contain express interfaces with human rights and public policy writ large. These interfaces typically take the form of specific human rights exceptions or general ones allowing the exercise of the “right to regulate.” This “right to regulate” in relation to IIAs may be defined as “a legal right that permits a departure from specific investment commitments assumed by a State on the international plane without incurring a duty to compensate.” At least in a functioning democracy, it could also be defined as “an affirmation of states’ authority to act as sovereigns on behalf of the will of the people.” Specific interfaces in IIAs provide for identified regulatory measures to be taken without violating their commitments and obligations contained in bilateral, regional or multilateral trade agreements. By contrast, general interfaces

---


224 AIKATERINI TITI, THE RIGHT TO REGULATE IN INTERNATIONAL INVESTMENT LAW 52 (2014).

225 Id.

226 WANDAH M'OYUL, supra note 165, at 8.
take the form of an open-ended exception affirming the state’s right to adopt certain regulations.

The most important general interfaces in international trade law are arguably the exceptions contained in GATT Article XX and GATS Article XIV. The latter targets, inter alia, measures “necessary to protect public morals or to maintain public order’, ‘necessary to protect human … life or health.”227 Similar exceptions are found in the trade portion of a number of IIAs.228 General interfaces do not prescribe the type of measure that can be taken by the state, only a standard against which they can be measured.229 Admittedly, recourse to general interfaces has not been very successful in the TRIPS context at the WTO, but then there have been relatively few cases.230

The TRIPS Agreement does contain both general and specific interfaces with human rights. It states, first, a general exception: “Members may adopt measures necessary to protect public health and nutrition, and to promote the public interest in sectors of vital importance to their socio-economic and technological development, provided that such measures are consistent with the provisions of this Agreement.”231 Second, TRIPS contains a specific exception allowing WTO members to exclude from patentability inventions “the prevention within their territory of the commercial exploitation of which is necessary to protect ordre public or morality, including to protect human, animal or plant life or health.”232 Both those TRIPS interfaces are cabined by the use of the term “necessary.”233 The use of this term seems to posit (as a normative matter)

227 GATT art. XX.
229 See id. at 333 (“… a new trend is emerging in treaty practice consisting of including a ‘general exceptions’ clause, which governments hope will provide greater regulatory flexibility and serve pursuing public interest objectives . . . ”).
231 TRIPS Agreement art. 8.1.
232 Id. art. 27.2.
233 See FRANKEL & GERVAIS, supra note 196, at 1205 (reviewing WTO jurisprudence and noting that the “Appellate Body further said, ‘[D]etermination of whether a measure, which is not “indispensable”, may nevertheless be “necessary” . . . involves in every case a process of weighing and balancing a series of
that trade liberalization commitments should trump but for the necessity to adopt certain regulatory measures. It does not specify the burden of proof (who must show necessity and how), but there is WTO jurisprudence on that point.234 Language matters.235 Providing a “right to regulate,” often in an IIA provision bearing that as its title, can be significantly constrained by a “provided that such measures are consistent with provisions of this Agreement” clause, as in TRIPS Article 8.1 for example.236 Then the right to regulate might be a general “public interest” clause offering broad flexibility, but it may also limit the scope to specific public interests (plural), such as labor or environmental standards.237 Another consideration is that a country that adds this right to regulate (as the United States did in its model BIT in 2004) might prompt an investor to argue that earlier IIAs do not, a contrario, provide regulatory flexibility.238

Professors Dinwoodie and Dreyfuss proposed a “neofederalist” model of international IP in the TRIPS context that offers additional guidance on the interpretation of exceptions. Their approach considers an international acquis that the DSB should incorporate into the TRIPS framework using both general and specific interfaces.239 As they note, now that trade and intellectual property were joined at the hip (by the TRIPS Agreement) “linkage to a broader array of norms is inevitable.”240 They argue “detaching TRIPS adjudication from the rich fabric of other international initiatives would distort the creative environment and ignore important values, such as commitments to free speech and distributive justice.”241 They suggest, inter alia, factors which prominently include the contribution made by the compliance measure to the enforcement of the law or regulation at issue, the importance of the common interests or values protected by that law or regulation, and the accompanying impact of the law or regulation on imports or exports.

234 See id. at 1206–1207.
235 See TITI, supra note 224, at 111–15.
236 See id.
237 See id. at 99–100.
238 See id. at 295.
239 DINWOODIE & DREYFUSS, supra note 230, at 160.
240 Id.
241 Id.
that the DSB make more room for general exceptions, which states often use to safeguard “interests outside intellectual property.”

Clearly, there is still work to be done—some of it by the WTO Appellate Body—to clarify the trade and intellectual property interface. Yet doctrinal avenues have been ploughed, at least at the theoretical level. The pending plain packaging cases at the WTO may present an occasion for the Appellate Body to put some of them in actual motion. Can that help solve our ISDS challenge?

2. ISDS

Express interfaces between the right to regulate and ISDS increasingly often find their way in the investment chapter of IIAs, sometimes with the specific purpose to exclude an evaluation by an ISDS tribunal or substantive intellectual property rules, or to maintain regulatory flexibility (and in the latter case sometimes a link is made with human rights, as the examples discussed in the following lines should demonstrate.) In both the Comprehensive Economic and Trade Agreement (CETA) and Transatlantic Trade and Investment Partnership (TTIP), substantive intellectual property is at least partly excluded from ISDS scrutiny, for example, a move perhaps informed by the filing of the Lilly case. Indeed the Tribunal in that case did not hesitate to equate patents with investment—even though a patent may be issued in a country where none of the expenses related to the development of the invention took place.

The exclusion of IP was done in CETA by adding a declaration that provides both that “investor-State dispute settlement tribunals . . . are not an appeal mechanism for the decisions of domestic courts,” and that “the domestic courts of each Party are responsible for the determination of the existence and validity of intellectual property rights.” Moreover, CETA reasserts “each Party shall be free to determine the appropriate method of implementing the provisions of this

242 See id. at 186.

243 See FRANKEL & GERVAIS, supra note 196, at 1214 (“[T]here is a need for a balanced and methodical approach by the WTO. Both the VCLT and previous panel and Appellate Body reports contain the tools that are needed to get to a balanced outcome.”).

244 Eli Lilly and Co. v. Gov’t Canada, ICSID Case No. UNCT/14/2, Final Award, ¶106 (Mar. 16, 2017), http://icsidfiles.worldbank.org/icsid/ICSIDBLOBS/OnlineAwards/C3544/DC10133_En.pdf ¶ 167.

Agreement regarding intellectual property within their own legal system and practice.” In October 2016, after opposition from the French-speaking part of Belgium, it was agreed that the ISDS provisions of CETA would be submitted to the Court of Justice of the European Union to determine their compatibility with EU law, in particular the ability of EU member States to implement and enforce public policy and fundamental rights.

Similarly, the European text proposal for the TTIP provides that:

For greater certainty, the revocation, limitation or creation of intellectual property rights to the extent that these measures are consistent with TRIPS and Chapter X (Intellectual Property) of this Agreement, do not constitute expropriation. Moreover, a determination that these actions are inconsistent with the TRIPS Agreement or Chapter X (Intellectual Property) of this Agreement does not establish that there has been an expropriation.

The free trade agreement between Australia and the United States also contains a general carve out in ISDS for public health purposes. NAFTA parties presumably could add a similar one to Chapter 11 (with the risks that any reopening of NAFTA entails,) or one similar to the exclusion added to CETA, and in the EU-proposed TTIP text if doubts as to the intent and meaning of Article 1110(7) remain.

An interesting change can also be observed in the model U.S. BIT. The initial model dates back to 1977 and its main focus was on the protection of foreign investments by U.S.

---

246 Id. at art. X.11, ¶ 6; see also Vadi, supra note 77, at 191.
250 See Melissa Long, Recent Developments in NAFTA, 14 L. & BUS. REV. AM. 875, 879 (2008) (noting that under President George W. Bush, the “Administration has been and will continue to be clear and consistent in strongly opposing requests to reopen this agreement” due to risk to US exporters.).
251 See supra note 84, and accompanying text.
252 See MOUVAL supra note 165, at 71–73.
In the wake of ISDS cases against the United States and the increasing recognition that “bilateral” implies that foreign companies can invest in, and sue the government of, the United States, the model BIT was revised in 2004 to note that “[e]xcept in rare circumstances, non-discriminatory regulatory actions by a Party that are designed and applied to protect legitimate public welfare objectives, such as public health, safety and the environment, do not constitute indirect expropriations.” The avenue explored there—namely the systematic exclusion of an evaluation of compliance with substantive intellectual property obligations by ISDS tribunals—is common in more recent trade agreements concerning other key areas, such as labor, environment and sustainable development. Indeed they are contained in the majority of post-WTO (1995) trade agreements negotiated by the EU. They often refer to a list of international conventions setting out applicable standards that a state (or the EU itself) has the right to implement. Safeguards for labor, environment and sustainable development often explicitly demand a “high level of protection” and put these interests expressly above that of liberalization of trade. For example, under Article 23.2 of CETA, the parties “seek to ensure those laws and policies provide for and encourage high levels of labour protection and shall strive to continue to improve such laws and policies with the goal of providing high levels of labour protection.”

253 See id.

254 2012 U.S. MODEL BIT, Annex B(4)(b), supra note 56 (The 2012 language is unchanged on this point from the 2004 model, as a request to remove “except in rare circumstances” was rejected). See MOUYAL, supra note 165, at 72.

255 CETA, supra note 245, arts. 22.1, 23.2, 24.3; Free Trade Agreement between the European Union and the Republic of Singapore art. 13.1(1) [hereinafter E.U.-Singapore FTA]; Free Trade Agreement between the European Union and Its Member States, of the One Part, and Colombia and Peru, of the Other Part arts. 269(3), 270(2) [hereinafter E.U.-Peru & Columbia FTA]; Agreement Establishing An Association Between Central America, On The One Hand, And The European Union And Its Member States, On The Other arts. 286(1)-(2) [hereinafter E.U.-Central America Association Agreement]; Free Trade Agreement between the European Union and its Member States, of the one part, and the Republic of Korea, of the Other Part arts. 13.4, 13.5 [hereinafter E.U.-Korea FTA].

256 See articles of agreements cited supra note 255.

257 A similar provision is contained in Article 13.2(2) of the E.U.’s Free Trade Agreement (FTA) with Singapore and in Article 268 of the E.U.’s FTA with Colombia and Peru.
In addition to these provisions, some IIAs include recognition by the parties that “it is inappropriate to encourage trade or investment by weakening or reducing the protections afforded in domestic labour and environment laws.” 258 The Association Agreement between the EU and Central America goes a step further in its Article 291(2) which requires parties “not to waive or derogate from, or offer to waive or derogate from, its labour or environmental legislation in a manner affecting trade or as an encouragement for the establishment, acquisition, expansion or retention of an investment or an investor in its territory.” 259 In addition, paragraph three demands that a party “shall not fail to effectively enforce its labour and environmental legislation in a manner affecting trade or investment between the Parties.” 260

Systematic exclusion of certain policy areas, in whole or in part (that is, by applying a stricter test), is thus a clearly useful tool to consider as we now turn to this Article’s proposed solutions.

V. Specific Ways Forward

A. The Puzzle

The puzzle this Article attempts to contribute to solving is to build proper interfaces between a state’s right—indeed often its duty—to regulate to protect human rights and key public policy areas, on the one hand, and the protection of investment contained in thousands of IIAs when this protection takes the form of a complaint filed by a multinational corporation against a host state in an ISDS proceeding. States need “regulatory space of manoeuvre to promote social welfare . . . and to live up to international human rights commitments.” If the state’s hands are tied in such a way that it can no longer respond adequately to changing circumstances—whether those changes be social, environmental or technological—by adapting their social and economic policies, then the advantages that states see in encouraging foreign

258 E.U.-Singapore FTA art. 13.1(3); E.U.-Central America Association Agreement art. 291(1).
259 E.U.-Central America Association Agreement art. 291(2).
260 Id.
investment through ISDS will fade and trigger public opinion backlash—as recent European events have demonstrated. The sustainability of investment protection is at stake.

B. Parameters of an Optimal Human Rights/ISDS Interface

Is ISDS a way to circumvent shortcomings that companies see in state-to-state multilateral dispute settlement? The question is worth asking. Recall that ISDS was originally meant as defensive measure for companies stripped of assets by expropriation, often for purposes of nationalization of those assets by a state. ISDS has morphed into a “potent offensive strategic tool” to effectuate policy changes to domestic norms concerning environmental protection, intellectual property, and other regulatory areas. As far as intellectual property is concerned, as Joost Pauwelyn has observed, there have been few TRIPS cases, and some of them left a bitter after taste in the mouths of corporate actors who had pushed for the cases to be filed. Those cases were not rejected on the basis of human rights or extrinsic (non-WTO) norms, however.

The answer is not to oppose the grant to corporations (non-state actors) of a right to sue states. Governments may have incentives not to file cases against other governments, including lack of resources, diplomatic relations, etc. Non-state actors, including well-organized nongovernmental organizations (NGO), can supplement the “enforcement” activity of states.

261 See Peter Muchlinski, Policy Issues, in THE OXFORD HANDBOOK OF INTERNATIONAL INVESTMENT LAW 60 (Peter Muchlinski, Federico Ortino & Christopher Schreuer eds., 2008).
264 See generally Pauwelyn, supra note 83.
265 Id.
The issue with ISDS is different and specific. It is that only a very narrow category of non-state actors (multinational investors) have been given an extraordinary lever to achieve policy aims; tribunals with broad powers and dedicated to the task of investment protection have been established with a sole purpose: to hear their grievances about states.\footnote{The risk is that those firms will use ISDS as “vertical forum-shifting to achieve results that they know would be unacceptable if debated and considered openly and multilaterally.”} Some commentators have gone a step further and argued that flexibilities in trade rules could be “closed” using ISDS, such as exhaustion (parallel imports).

The question with respect to human rights is whether ISDS should interpret and “factor in” human rights obligations to “balance” investment protection in a deeper normative pool. As explicated in Part IV, some scholars believe that trade tribunals must consider human rights (including those that mesh with trade liberalization). Others carefully explicate how and why under the VCLT they can do so.\footnote{In this Article’s view, they most certainly can do so.} The constitutional and contract-based approaches reviewed in Part IV are certainly worth

\footnote{ISDS “remedies” are not an obligation to change the law but rather an obligation for the state at fault to compensate the complainant. However, the imposition or risk of imposition of very large awards (Lilly’s claim is in the order of C$500 million) will likely lead governments to effect policy changes or not make ones that multinational investors do not want to see implemented to avoid the disputes. See Dreyfuss & Frankel, supra note 163, at 574 (“When the United States failed to conform to the 1999 US-110(5) decision, it paid the EU, pursuant to further WTO arbitration, $3.3 million to cover a three-year period . . . In an investment dispute Eli Lilly brought against Canada over its patent rights, it demanded CDN $500 million. That difference could have a considerable impact on the willingness of countries to draft laws that test the limits of international flexibilities.”) (citations omitted).}

\footnote{Sell, supra note 153, at 177.}

\footnote{See Baker & Geddes, supra note 50, at 32 (“Article 6 prohibits resort to interstate dispute settlement with respect to IP exhaustion rules, but it does not directly permit or authorize international exhaustion, otherwise known as parallel importation. Accordingly, a disgruntled pharmaceutical company could very easily object to the importation and sale of a medicine it had sold more cheaply elsewhere claiming that parallel importation had violated its expectation of patent-based market segmentation and higher profits in certain markets.”) (footnote omitted).}

\footnote{Under the TRIPS Agreement, WTO members agreed to disagree on exhaustion. Article 6 of TRIPS provides that “[f]or the purposes of dispute settlement under this Agreement, subject to the provisions of Articles 3 and 4 nothing in this Agreement shall be used to address the issue of the exhaustion of intellectual property rights.” TRIPS Agreement, supra note 84, art. 6.}

\footnote{See Alvarez, supra note 116, at 42, 47–52.}
investigating, even though they lead to a risk that human rights and other key public policy objectives will play second fiddle in an orchestra of norms conducted by trade law.\textsuperscript{271}

This Article suggests that human rights obligations brought to the attention of an ISDS tribunal should be fully considered in interpreting the scope and depth of the regulatory leeway used by the State before an unjustified (that is, one that leads to an obligation to compensate the investor) violation of its investment obligations is found. How the second prong can be effectuated is discussed in the next section.

C. Directed Interpretation

An optimal solution to the puzzle described in the opening section of this Part would do more than just require ISDS tribunals to “consider” human rights obligations: dispute settlement bodies should be directed to avoid any interpretation of the IIAs that would contravene a human rights obligation undertaken by the State whenever possible, a global “Charming Betsy” doctrine, as it were.\textsuperscript{272} The VCLT indicates the path to follow: when a text’s meaning is obscure or ambiguous a broader context, including other relevant instruments can—some might say should—be factored in.\textsuperscript{273}

Applied to the ISDS context, following this proposed canon would mean that when an interpretation of the notions of direct or indirect expropriation and fair and equitable treatment in an investment protection chapter can be reconciled with a state’s regulatory autonomy in an area of vital socio-economic importance and/or a state’s implementation of its human rights obligations, then that interpretation should be preferred.\textsuperscript{274} This would have a “normative

\footnotesize
\textsuperscript{271} See generally Alston, supra note 4.
\textsuperscript{272} The Charming Betsy doctrine is a U.S. doctrine of statutory interpretation named after the schooner Charming Betsy seized in 1800 in open seas by a U.S. frigate. It led to a Supreme Court opinion, Murray v. Schooner Charming Betsy, 6 U.S. 64 (1804). The Supreme Court stated that an “act of Congress ought never to be construed to violate the law of nations if any other possible construction remains.” Id. at 118.
\textsuperscript{273} See supra Section II.C.
\textsuperscript{274} The “area of vital socio-economic importance” is taken from Article 8.1 of TRIPS. See supra note 231, and accompanying text (“Members may, in formulating or amending their laws and regulations, adopt measures necessary . . . to promote the public interest in sectors of vital importance to their socio-economic and technological development . . .”). On the interpretation of regulatory flexibility see also Robert Howse, The World Trade Organization 20 years On: Global Governance by Judiciary, 27 EUR. J.
stabilizing effect, at a time when there are few agreed answers about the costs and benefits of globalization or the ideal shape of global economic governance in relation to differing domestic policy paths.\textsuperscript{275} WTO jurisprudence on the use of regulatory flexibilities within boundaries set by trade commitments and obligations under WTO instruments could inform the determination of the appropriate scope and reach of the state’s regulatory elasticity.

As already detailed, an explicit mechanism exists at the WTO to effectuate this policy.\textsuperscript{276} In the ISDS context, it is admittedly harder. After all, there are thousands of existing IIAs that contain investment provisions.\textsuperscript{277} Realistically they cannot all be amended, although bulk actions, such as pulling out of all of them at once has been used.\textsuperscript{278} The idea of amending the VCLT itself, the provisions of which have achieved canonical status, also seems far-fetched.\textsuperscript{279} Issues of retroactive application of new interpretation norms that have no claim to customary law would emerge.\textsuperscript{280}

A different option would be to have a special convention. In early 2017, the EU launched consultations on a Multilateral Investment Court, a permanent court to be established

\begin{quote}
\textsuperscript{275} Howse, supra note 273, at 76.
\textsuperscript{276} Namely the general exception. See Chaisse, supra note 228.
\textsuperscript{277} See supra note 35 and accompanying text.
\textsuperscript{278} For example, in answer to questions at the Indian Parliament (Lok Sabha) on July 25, 2016, the Indian Minister of Trade and Industry noted that “[o]ut of the total 83 [bilateral investment] treaties signed by India so far, 58 treaties are being terminated.” See GOV’T OF INDIA, DEP’T OF INDUS. POLICY & PROMOTION (2016), http://dipp.nic.in/sites/default/files/jul1290.pdf.
\textsuperscript{280} Although this would require a longer discussion, VCLT art. 28 provides for non-retroactivity of treaties. As to the status of VCLT interpretive rules as customary international law, see Eirik Bjorge, The Vienna Rules on Treaty Interpretation before Domestic Courts, 131 L. QUART. REV. 78, 80 (2015), for a reference to “customary international law of treaty interpretation, as reflected in arts 31–33 of the Vienna Convention . . . .”) (footnote omitted).
\end{quote}
for this purpose in TTIP. That new court could theoretically come up with interpretive principles to the same effect as those described above, but this seems unlikely to the Author given that investment protection is ISDS’ normative lodestar. This Article suggests that “Vienna Plus” interpretive principles could be included in the convention (statute) establishing the new court to reflect recent understandings about ISDS. Naturally, if the new court only bound EU-related ISDS it would not directly affect IIAs not involving the EU. However, jurisprudence might emerge from this court that might influence other arbitral tribunals. If the court was established not as a “pure” EU court, but instead a multilateral one, it could attract other nations that would either reorient existing investor-state disputes arising out of existing IIAs or use it for future ones.

In the EU context, one must keep an eye on the referral to the Court of Justice of the European Union about CETA’s ISDS mechanism that the Walloons (French-speaking Belgians) obtained. The Court has already expressed doubts about the constitutional validity of “external” tribunals, especially when those tribunals’ findings may clash with the fundamental rights contained in the EU Charter.

---

281 See Questionnaire on options for a multilateral reform of investment dispute resolution, EUROPEAN COMMISSION, http://trade.ec.europa.eu/consultations/index.cfm?consul_id=233 (last visited March 30, 2018); see also Ben Stanford, Andreas Yiannaros, & Chrispas Nyombi, TTIP negotiations in the shadow of human rights and democratic values, 27 INT’L COMPANY & COM. L. REV., 316, 319 (2016) (“In November 2015, following an extremely critical public consultation into the ISDS model which is commonly used in similar but smaller-scale trade agreements, the Commission revealed that it would instead pursue proposals for an investment court to be included in the TTIP.”) (citations omitted).

282 See supra text accompanying note 190.


284 Wallonia obtained that the EU Commission should ask the Court of Justice of the European Union to examine the compatibility of the ISDS provisions contained in CETA with EU Law, in particular the EU Charter of Fundamental Rights. See Milan Schreuer, How Dairy Farmers in Belgium Held Up a Big E.U. Trade Deal, N.Y. TIMES, (Oct. 28, 2016), http://nyti.ms/2nskp4y.

285 See Ernst-Ulrich Petersmann, Can the EU’s Disregard for “Strict Observance of International Law” (Article 3 TEU) Be Constitutionally Justified?, in TRADE AND COMPETITION LAW IN THE EU AND BEYOND (Inge Govaere, Reinhard Quick & Marco Bronckers eds., 2011).
D. Expressly Reserving Regulatory Autonomy

A strongly worded interface should direct ISDS tribunals to refrain from stepping on the regulatory autonomy of States promoting their population’s public health, both because these are sectors of “vital importance”—to use the terminology of TRIPS Article 8.1—and because the regulatory measures at issue are a means of implementing the right to health. This is particularly true in patent cases concerning pharmaceuticals because in such cases looking solely at an investor’s alleged losses misses several key parts of the policy picture. This can be done negatively by limiting the scope of ISDS, or positively by adding to investment instruments an appropriately worded “right to regulate” clause.

A good example is the exclusion of substantive IP rules from ISDS in both CETA and TTIP. The European Union is not alone. Recall that both Mexico and the United States came to Canada’s defense in the Lilly case, not as much on the interpretation of the patent provisions of NAFTA, but in the role of ISDS in this context. Australia supported the inclusion of a countervailing right to regulate to limit the reach of “pure” investment rules rather than by restricting the scope of ISDS. In a statement on trade policy issued in 2011, the government of Australia noted that it “does not support provisions that would confer greater legal rights on foreign businesses than those available to domestic businesses. Nor will the Government support provisions that would constrain the ability of Australian governments to make laws on social, environmental, and economic matters in circumstances where those laws do not discriminate between domestic and foreign businesses.”

E. Imposing Obligations on Investors

The marked reluctance of international investment law to “take adequate account of the public interest and to integrate principles from international environmental and human rights law

---

286 Previous IIAs were bilateral, that is, entered into not by the E.U. but with individual member states.
287 Interestingly, CETA was the first E.U. IIA containing an ISDS mechanism. See supra note 245 and accompanying text.
is out of step with current trends in public international law.”

Would imposing obligations on investors—perhaps using the doctrine of stipulation for another—that at present claim rights under ISDS provisions lead to a more balanced outcome?

Weisbrodt and Kruger asked whether it was “appropriate to place human rights obligations upon organizations whose primary purpose is to produce profit or effectively deliver goods or services.”

They answer in the affirmative, noting that a “widely accepted” set of human rights norms would create more predictability and “establish a level playing field for business competition.”

Ratner has argued along similar lines that “business enterprises will have duties both insofar as they cooperate with those actors whom international law already sees as the prime sources of abuses—states—and insofar as their activities infringe upon the human dignity of those with whom they have special ties.”

Yet, one must admit that, as Forman and Kohler rightly note, “the application of human rights to non-state actors like the pharmaceutical industry is not a settled question within international law.”

Still, at the domestic level at least, India and South Africa have cases demonstrating that domestic courts can impose access obligations on patent holders based on the human right to health.

A possible forum for further discussion on this issue is the Organisation for Economic Co-operation and Development (OECD), which is discussing National Action Plans on Business and Human Rights (NAPs) as part of its Responsible Business Conduct Initiative.

F. Factoring in Unintended Consequences

290 Miles, supra note 146, at 296.

291 See previous Section IV.C.3.


293 Id. at 335–336.


Unintended consequences are so common that their existence is said to be a “law.”\textsuperscript{298} A win for Lilly in its ISDS claim against Canada would likely have had unintended consequences. A win for Lilly would have created a strong incentive for patent offices to be extremely (or at least more) careful in the pharmaceutical sector in the case of dubious applications—perhaps such as the “species within a genus” type of application at issue in the Lilly case—and possibly other industrial fields where major multinational players have the wherewithal to challenge a state’s invalidation decisions in an ISDS and claim compensation from its taxpayers.\textsuperscript{299} A second incentive logically created by a win would have been that patent offices should look long and hard before issuing pharmaceutical patents if their state coffers are then tapped for compensation in case of invalidation seen as indirect expropriation or a failure to meet some FET standard in an ISDS context. How this would have benefited Lilly and other pharmaceutical companies is not entirely obvious.

**CONCLUSION**

Lilly lost the gamble it played when filing its C$500 million investor-state dispute against Canada.\textsuperscript{300} The case did, however, provide scholars and the investment law community with a unique opportunity to reflect on the balancing of intellectual property, investment, human rights and regulatory autonomy. This Article briefly reviewed the arguments made by both parties, the award, and mechanisms that exist to bridge the normative and doctrinal gaps between intellectual property, human rights, trade, and investment, bearing in mind important differences between

---


\textsuperscript{299} The rule against double-patenting prevents an applicant from claiming a genus if an earlier-issued patent contains claims to a species of the genus because the genus is anticipated by the species but a claim to a genus does not prevent a claim to a species within the genus. As the Federal Circuit noted in a case (involving Lilly in fact): “[C]ase law firmly establishes that a later genus claim limitation is anticipated by, and therefore not patentably distinct from, an earlier species claim.” Eli Lilly & Co. v. Barr Labs, Inc., 251 F.3d 955, 971 (Fed. Cir. 2001), cert. denied, 534 U.S. 1109 (2002).

\textsuperscript{300} Although Lilly’s loss was followed by a win, namely the surprising and weakly supported reversal of policy by the Supreme Court of Canada a few months later. See AstraZeneca Canada Inc. v. Apotex Inc., [2017] 1 S.C.R. 943 (Can.).
trade (state-to-state) and investor-state disputes. It proposes several paths forward to prevent future disputes from taking investment state disputes outside proper channels.